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Summary 
 
Oesophageal cancer (OC) is the sixth leading cause of cancer related deaths in the world with 
approximately 300 000 new cases reported each year.  OC may be characterized into two 
forms with 90% of cases presenting as squamous-cell carcinoma (SCC) and the remaining 
10% as adenocarcinoma (ADC).  Several factors have been attributed to the development of 
OC, including oesphageal injury and/or irritation, chronic inflammation and excess iron 
associated with enhanced tumour growth. 
The HAMP gene codes for a 25 amino-acid protein found to be primarily expressed in the 
liver and crucial to regulation of bodily iron status.  Defects occurring in the HAMP gene 
could therefore lead to the dysregulation of the gene, resulting in an iron overload status. Iron 
overload is a previously described risk factor in the development of various cancers, 
including OC, and therefore the aim of this study was to investigate whether dysregulation of 
the HAMP gene may be involved in the cancer phenotype exhibition.  
The study cohort comprised of 48 unrelated patients presenting with SCC and a control group 
of 51 healthy, unrelated population-matched individuals.  Mutation detection techniques 
included polymerase chain reaction (PCR) amplification, heteroduplex single-stranded 
conformation polymorphism (HEX-SSCP) analysis and bi-directional semi-automated DNA 
sequencing analysis.  Screening of the 5’ regulatory region (5’UTR) of the HAMP gene 
revealed one known (-582A/G) and two novel (-188C/T and -429G/T) variants with the  
-429G/T variant showing statistically significant reduction in expression in patients relative 
to controls.  Iron parameters were correlated between patient and control cohorts, as well as 
for variant presence and absence within individuals.  Luciferase reporter constructs were used 
to investigate the functional implications of the presence of a variant on HAMP gene 
expression, and how these results correlated to the iron parameter statistics obtained. 
Luciferase reporter assay results indicated the -188C/T and -429G/T variants to result in 
under-, and the -582A/G variant to result in over-expression at the basal level, relative to the 
respective wild-type sequence constructs.  Correlation of the luciferase data with the iron 
parameter statistics, indicate the -429G/T variant to be coupled to significantly higher levels 
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of ferritin and C-reactive protein (CRP) and significantly lower levels of serum-iron and 
transferrin when compared to individuals without the variant.  Considering only the patient 
group, the presence of the -188C/T and -429G/T variants were coupled to significantly lower 
levels of transferrin in patients with either variant, compared to patients without.  The 
variants found within the HAMP promoter region are therefore able to alter gene regulation to 
an extent where iron parameters deviate between healthy and OC afflicted individuals, and 
also between patients with and without a variant.  This dysregulation in iron homeostasis may 
play a role in the development and/ or progression of OC.  Characterisation of the 5’ UTR of 
the HAMP gene may contribute to linking iron regulation to the establishment of an effective 
screening program, facilitating the early detection of OC. 
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Opsomming 
 
Slukdermkanker (SK) is die sesde grootste oorsaak van kanker-verwante sterftes in die 
wêreld, met sowat 300 000 nuwe gevalle wat aangemeld word elke jaar. SK kan 
geklassifiseer word in twee vorme, waar 90% van die gevalle plaveisel-selkarsinoom (SSC) 
vorm en die oorblywende 10%, adenokarsinoom (ADC). Verskeie faktore word toegeskryf 
aan die ontwikkeling van SK, insluitend slukderm beserings en/ of irritasie, chroniese 
inflammasie en oormatige ystervlakke wat geassosieer word met verhoogde gewasgroei. 
  
Die HAMP geen kodeer vir 'n 25 aminosuur proteïen wat hoofsaaklik in die lewer uitgedruk 
word en noodsaaklik is vir die regulering van ystervlakke in die liggaam. Defekte wat in die 
HAMP geen voorkom kan dus die onreëlmatige regulering van die geen tot gevolg hê, wat lei 
tot yster-oorlading. Yster-oorlading is voorheen beskryf as ‘n risiko faktor in die 
ontwikkeling van verskillende vorme van kanker, insluitend SK en gevolglik was die doel 
van hierdie studie om te bepaal of die wanregulering van die HAMP geen betrokke mag wees 
by die uitdrukking van die kanker fenotipe. 
  
Die studiepopulasie het bestaan uit 48 onverwante pasiënte met SSC en ‘n kontrole-groep van 
51 gesonde, onverwante soortgelyke individue. Die mutasie opsporingstegnieke wat gebruik 
is, het polimerase kettingreaksie (PKR) amplifisering, heterodupleks enkelstring-konformasie 
polimorfisme (HEX-SSCP) analise en bidireksionele semi-outomatiese DNS 
volgordebepaling-analise van die geïdentifiseerde variante ingesluit.  Sifting van die 5’ 
regulerende area (5'UTR) van die HAMP geen het een bekende  
(-582A/G) en twee nuwe (-188C/T en -429G/T) variante opgelewer, met die -429G/T variant 
wat statisties beduidend onderdruk is in pasiënt  uitdrukkings vlakke relatief tot 'n gesonde 
kontole-groep. Yster-parameters van alle pasiënt en kontole individue is gekorreleerd tussen 
pasiënt en kontrole groepe, sowel as vir teenwoordigheid of afwesigheid van variante in elke 
individu. Luciferase verklikker konstrukte is gebruik om die funksionele implikasies van die 
teenwoordigheid van ‘n variant op HAMP geenuitdrukking te ondersoek, en hierdie resultate 
te korreleer met yster-parameter statistieke wat verkry is. 
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Luciferase verklikkertoetse dui aan dat die -188C/T en -429G/T variante tot verminderde, en 
die -582A/G variant lei tot die verhoogte uitdrukking op die basale vlak lei, relatief tot die 
onderskeie wilde-tipe konstukte. Korrelasie van die luciferase data met die yster-parameter 
statistieke, dui aan dat die -429G/T-variant gekoppel is aan aansienlik hoër vlakke van 
feritien en C-reaktiewe proteïen (CRP) en beduidend laer vlakke van serum-yster en 
transferrien in vergelyking is met individue sonder die variant. Met oorweging van slegs die 
pasiënt-groep, is die teenwoordigheid van die -188C/T en -429G/T variante beduidend 
gekoppel aan laer vlakke van transferrien in pasiënte met die variant, in vergelyking met 
pasiënte daarsonder. Variante binne die HAMP promotor is dus in staat om geenregulasie te 
verander tot so 'n mate dat die yster-parameters afwyk tussen gesonde en SK geaffekteerde 
individue, sowel as tussen pasiënte met en sonder ’n variant. Hierdie wanregulering in yster 
homeostase kan 'n rol speel in die ontwikkeling en/ of die progressie van SK. Karakterisering 
van die 5’ regulerende area van die HAMP geen kan grootliks bydra om ysterregulasie te 
verbind met die implementering van ‘n effektiewe siftingsprogram, en sodoende die vroeë 
opsporing van SK fasiliteer. 
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1. Literature Review 
 
 
1.1. A brief history of iron 
 
Iron represents 4.7% of the earth’s crust, taking the forms of magnetite, hematite and siderite, 
making it the fourth most abundant earthly element.  It is of absolute necessity to all forms of 
life with the exception of a few bacterial genera which have evolved to a point where they are 
able to use other metals adjacent to iron in the periodic table in order to survive.  The 
biological importance of the iron trace element remains undisputed with it being an essential 
cofactor or constituent of an enormous array of protein and enzymatic elements vital in 
cellular metabolism (Beard et al., 1996). 
Although ancient cultures were unaware of the valuable importance of iron they were 
seemingly aware of its therapeutic properties. Ancient Greeks administered iron to injured 
soldiers as a treatment for weakness.  This weakness experienced was probably due to anemia 
resulting from immense blood loss of the wounded.  Sixteenth century physicians prescribed 
iron as a medicinal treatment for some patients believed to have, what is now known to be, 
iron deficiency.  In the early eighteenth century iron was shown to be an important 
component of the liver and blood and hemoglobin content was, remarkably, quite accurately 
estimated. The nutrition essentiality of iron was first described in 1872 and a ‘mucosal block’ 
theory was first described by Granick in 1946 (Granick, 1946; Beard et al., 1996).  
Observations regarding the significance of iron in health and nutrition were clearly made 
quite some time ago; however, the actual mechanisms concerning iron metabolism at the 
molecular level are only now being illuminated. 
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1.2. Introduction to iron metabolism 
 
Iron is an important trace element within the body as an important constituent of many 
enzymes required for critical cellular function, and is therefore essential to good health.  Iron, 
however, also possesses the ability to catalyze the creation of reactive oxygen species which 
can prove damaging to tissues.  It is for this reason that the presence of excess amounts of 
iron within bodily tissues be expressly limited.  The double-edged sword nature iron therefore 
necessitate its regulation by precise systems ensuring that there are optimum amounts of iron 
available to bodily tissues at any particular time. The body lacks an active mechanism for 
iron excretion and therefore bodily iron levels are primarily regulated at absorption level in 
the proximal end of the small intestine (reviewed by Anderson et al., 2005). 
Dietary iron exists in two forms within the body, namely as inorganic iron or as iron bound to 
heme.  The inorganic form is found to be most prevalent in the diet comprising approximately 
90% of standard dietary iron intake, while the remaining 10% is iron bound heme.  Heme is 
derived primarily from myoglobin and hemoglobin and is therefore associated with meat 
intake.  However, although heme iron is in the minority concerning dietary intake, it is 
absorbed much more efficiently and may therefore contribute quite substantially to the 
amount of iron that enters bodily tissues (Carpenter and Mahoney, 1992).    Ingested heme 
iron is released from proteins such as myoglobin and hemoglobin by proteolytic activity in 
the stomach and small intestine.  This heme may then be directly taken up by intestinal 
enterocytes.  The fact that iron remains bound to heme for uptake acclaims to the higher 
bioavailability of iron in this state since it is not vulnerable to the binding of a wide variety of 
the alternate dietary substances present (Hallberg, 1981). 
Iron is a vital component of nearly all living organisms and is essential to numerous 
metabolic processes. The development of erythroid cells; DNA, RNA and protein synthesis; 
electron transport; cellular respiration, proliferation and differentiation all contain steps to 
which iron, the most abundant metal in the body, is a crucial constituent (Lieu et al., 2001).  
Iron represents approximately 35 mg/kg body weight in adult women and 45 mg/kg body 
weight in adult men with the majority of iron (60 – 70%) being present in the hemoglobin of 
circulating erythrocytes (Bothwell et al., 1995; Conrad et al., 1999).  A further 10% can be 
found in iron-containing enzymes, myoglobins and cytochromes; and the final 20 – 30% as 
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excess iron stored in hepatocytes and reticuloendothelial macrophages as ferritins and 
hemosiderins (Conrad et al., 1999).   
 
The exclusivity of iron lies in its ability to either accept or donate electrons in an oxidation-
reduction reaction also known as the Fenton Reaction (Wessling-Resnick, 1999): 
Fe3+ + 
.
O2-  Fe2+ + O2;  Fe2+ + H2O2  Fe3+ + 
.
OH + OH- 
Iron may thus exist in either the insoluble ferric (Fe3+) or soluble ferrous (Fe2+) forms within 
the body.  The strict control of intracellular iron levels are of the utmost importance due to 
the ability of iron to create reactive oxygen species (ROS), which is highly toxic to the cell.  
ROS, such as hydroxyl (OH-) and superoxide (.O2) molecules, possess the ability to react with 
almost any molecule present within living tissues, including DNA.  The net effects of ROS 
induced DNA damage comes at great expense to bodily tissues when considering the possible 
impairment of cellular function which may result in inadequate or aberrant protein synthesis, 
impaired membrane lipid and carbohydrate formation and altered cellular proliferation 
(McCord, 1998).  Highly refined mechanisms have been put in place to insure the storage of 
iron in soluble, non-toxic forms and to enable control of the body’s iron homeostasis (Lieu et 
al., 2001). 
 
1.3. Iron regulation, uptake and storage 
 
Iron, being involved in a number of cellular functions, needs to be effectively absorbed, 
transported, stored and utilised to ensure the maintenance of iron homeostasis. Considering 
mammalian cells, the key molecules participating in iron metabolism are regulated by the 
amounts of intracellular iron levels present, which are brought about by using regulatory 
feedback machinery involving mRNA-protein interactions within the cell cytoplasm.  In an 
iron deficiency event, iron regulatory proteins bind to specific mRNA containing stem 
structures known as iron responsive elements.  Iron regulatory proteins then control the 
expression of iron target genes by either inhibiting the translation of iron response element-
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containing genes or increasing mRNA stability.  The implementation of this iron regulatory 
feedback mechanism ensures an appropriate level of intracellular iron essential to an array of 
cellular processes (Lieu et al., 2001). 
 
1.3.1. Iron-mediated feedback mechanism 
 
Both the sequences and structures of iron responsive elements (IREs) attest to their binding 
affinity for the aforementioned iron regulatory elements (Theil et al., 1994, 1999).  The stem-
loop structure of IREs consists of a terminal hexa-nucleotide loop and a base-paired stem 
structure separated by an unpaired cytosine nucleotide residue (Haile, 1999).  Variation 
occurring in the hexa-nucleotide structure or at the position of the unpaired cytosine 
nucleotide can significantly alter the binding affinity of iron regulatory proteins (IRPs) to 
IREs.  IREs are located in the 5’ untranslated region (5’UTR) of many genes as well as in the 
3’ untranslated region (3’UTR) of some mRNA molecules.  Depending on the location of 
these responsive elements they may act as either enhancers or repressors of translation (Theil 
et al., 1994).  Referring to mRNA, the binding of iron regulatory proteins may prevent the 
binding of the translation pre-initiation complexes thus preventing protein synthesis, or, 
increase mRNA stability and thereby increasing protein synthesis. 
 
1.3.2. Iron regulatory proteins (IRPs) 
 
The regulatory proteins, iron regulatory protein 1 (IRP1) and 2 (IRP2) bind directly to iron 
responsive element-containing RNA.  IRP1 can be found in all tissues with higher expression 
levels found in the liver, kidneys and intestinal tissues (Henderson et al., 1993).  The IRP1 
shows sequence similarity to cytoplasmic aconitases (an enzyme which catalyzes the 
conversion of citrate to isocitrate in the citric acid cycle) and has been shown to have 
aconitase activity similar to that of the mitochondrial aconitase. When normal iron levels 
prevail, the IRP1 contains an iron-sulphur cluster bound to three cysteine residues (Emery-
Goodman et al., 1993; Kaptain et al., 1991).  This form possesses aconitase activity but lacks 
the ability to bind RNA effectively.  Under conditions of iron deficiency the enzyme lacks the 
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iron-sulphur cluster needed for aconitase activity causing it to accumulate within the cell.  
This form, lacking aconitase activity, possesses the ability to bind to IREs with a high affinity 
(Rouault et al., 1992). 
IRP2 exhibits a 50% amino acid homology with IRP1 and binds to iron responsive elements 
with a similar affinity.  It too is expressed in most bodily tissues, but with reduced expression 
levels relative to IRP1.  The mechanisms of binding to IRP2 can also be compared to that of 
IRP1, but it is in the mechanisms responsible for the changes in iron-responsive element-
regulatory protein binding activity between the two proteins that are individual of each other 
(Guo et al., 1994; Henderson et al., 1993).  Then main difference between the two IRPs is 
that IRP2 is degraded more rapidly under conditions of high intracellular iron levels.  The 
mechanism for this degradation remains unclear, but it is believed that an inimitable region 
comprising of 70 amino acids is responsible for the degradation in response to high iron 
levels within the cell (DeRusso et al., 1995).  In addition, although both IRPs bind iron 
responsive elements with similar affinities, they are remarkably dissimilar in the sequence 
regions of the IREs to which they bind.  IRP2 is also missing amino acid residues required for 
the aconitase activity that IRP1 possesses (Phillips et al., 1996; Samaniego et al., 1994).  
Furthermore IRP2 also contains conserved cysteine residues necessary for iron-sulphur 
cluster formation, although, it is apparent that unlike IRP1, its RNA binding activity in not 
regulated by iron-sulphur clusters.  The differences between IRP1 and IRP2 suggest that they 
perform unique functions in response to the cellular status of iron and are probably acting on 
different targets.  There are, however, animal models in place that indicate that IRP2 is able 
to compensate for any loss of function occurring to IRP1 (Rouault and Klausner, 1997). 
 
1.3.3. Ferritin 
 
Free iron has the ability to form hazardous ROS and, therefore, the source of intracellular 
iron is ferritin.  This method of storage depicts a solution to the formation of free radicals 
without removing the crucial supply of iron from the cell entirely.  Ferritin exists in two 
subunits, namely, the heavy and light chains.  These subunits form a protein shell that enable 
the storage of up to 4500 iron molecules.  The execution of sequence analysis on the 5’ 
untranslated regions of ferritin mRNAs are sufficient to allow for iron-mediated regulation of 
Chapter 1: Literature Review 
7 
 
these molecules (Aziz and Munro, 1987).  It may also be noted that a cis-acting element, the 
acute box, is present downstream in the 5’ untranslated region of the mRNA of the ferritin 
heavy and light chains.  This box has the ability to regulate ferritin synthesis independently of 
the iron regulatory protein-mediated pathways (Rogers et al., 1994).  Furthermore a trans-
acting RNA binding protein (Rouault et al., 1987) has the ability to bind to the acute box in 
hepatic cells, where if mutations prevent this, there is interference in the formation of the pre-
initiation complex and reduction in the level of ferritin synthesis.  Ferritin synthesis is 
therefore regulated by both mRNA elements as well as RNA binding proteins, acting together 
or independently, in response to variating and alternate stimuli. 
 
1.4. Dietary iron uptake 
 
In the intestinal lumen iron is found to exist in the forms of ferrous and ferric salts.  Ferric 
forms of iron are insoluble at pH values above 3 and therefore need to be either reduced or 
chelated to ensure effective and efficient absorption (Conrad et al., 1999).  The ferrous forms 
of iron remain soluble even at pH 7 and are much more easily absorbed by the body.  Most 
dietary iron occurs in the form of ferric salts and, in order to permit efficient dietary iron 
absorption, it undergoes reduction mediated by the mucosal ferrireductase enzyme present in 
the intestines.  Alternatively ferric iron uptake may occur via the paraferritin pathway; 
however, this is a much less efficient mechanism of ferric iron absorption (Conrad et al., 
1999). 
 
1.4.1. Non-heme iron absorption 
 
Absorption of both the heme and non-heme forms of iron occurs in the proximal end of the 
small intestine, distinctively in the crypt cells of the duodenum and jejunum.  To enter the 
body’s circulatory system, dietary iron is required to pass across the apical membrane (Fig 
1.1), submit to translocation across the cytosol and finally export across the basolateral 
membrane of the enterocyte into circulation.  The apical surfaces of the absorptive 
enterocytic cells contain no transferrin receptors preventing iron from entering the cell via the 
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usual transferrin-transferrin receptor pathway. Iron absorption across the apical membrane is 
mediated by (natural resistance-associated macrophage protein 2 (NRAMP2)), also known as 
divalent cation transporter 1 (DCT1) or divalent metal transporter 1 (DMT1), a divalent 
cation transporter (Fleming et al., 1997; Gunshin et al., 1997).  
It is known that the NRAMP2 gene encodes two alternate spliced forms of mRNA.  The 3’ 
untranslated region of NRAMP2 isoform 1 contains an iron responsive element similar to that 
present in the mRNA of transferrin receptor 1 (TRF1) (Fleming et al., 1998), whereas 
isoform 2 lacks the iron responsive element.  Although NRAMP2 is expressed in a multitude 
of different tissues, significantly higher expression levels are observed at the duodenum brush 
border; validating its role in the intestinal absorption of iron into the enterocytic cytosol 
(Gunshin et al., 1997).  The NRAMP2 protein consists of 12 transmembrane domains and is 
located on the plasma membrane (Su et al., 1998).  NRAMP2 is an acting proton-coupled 
divalent cation transporter capable of transporting ferrous iron as well as a broad range of 
alternate divalent cations (Gunshin et al., 1997). 
 
1.4.2. Heme iron absorption 
 
Organic iron sources are absorbed much more efficiently than inorganic iron forms.  
Hemoglobin and myoglobin iron is initially digested in the intestinal lumen, and the resulting 
heme molecule may then enter the enterocytic cell as an intact metalloporphyrin entity 
(Majuri and Grasbeck, 1987).  The heme molecule enters the cell via a heme receptor-
mediated internalisation process (Mills and Payne, 1995), and once internalised is 
subsequently degraded by the heme oxygenase enzyme and iron is released as inorganic 
ferrous iron. As a result of the aforementioned enzymatic activity, inorganic iron now present 
within the enterocyte may either be stored as ferritin or be transported across the basolateral 
membrane and into the body circulation via the protein ferroportin-1 (FPN1). Any iron in the 
ferritin form still present at the end of the cell cycle will be lost along with the senescent cells 
representing an important mechanism of iron loss in humans. 
FPN1 is expressed in the placenta, liver, spleen, macrophages, kidneys and intestines.  The 
gene has an open reading frame of 562 amino acids and functional studies show that 
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ferroportin1 mediates iron efflux across membranes (Donovan et al., 2000; McKie et al., 
2000).  The membrane bound protein is thought to function in association with the membrane 
bound hephaestin and serum protein ceruloplasmin (McKie et al., 2000).  Ceruloplasmin and 
hephaestin are highly similar and function to facilitate the transport of iron into the body’s 
circulation. 
Fig 1.1 Schematic representation of the process of iron absorption in the GIT lumen.  Iron 
enters the enterocytic cell across the apical membrane by aid of DMT1, and exits the 
enterocytic cells, across the basolateral membrane, by aid of the membrane-bound FPN 
protein.  Haem may enter the enterocyte directly by means of HCP1, where it is then acted 
upon by HMOX1, releasing free ferrous iron into the intracellular iron pool.  Membrane-bound 
HEPH and plasma CP are responsible for the conversion of ferrous to ferric iron, allowing it to 
bind to transferrin and be transported to other areas of the body.  The hepcidin protein is able 
to bind to FPN, causing is subsequent internalization and degradation, limiting iron absorption 
in the intestinal lumen. (HCP1: Haem carrier protein -1, CYBRD1: cytochrome-b reductase-1, 
DMT1: divalent metal transporter 1, HMOX1: haemox reductase 1, FPN: ferroportin, HEPH: 
hephaestin, CP: ceruloplasmin, Fe2+: ferrous iron, Fe3+: ferric iron) 
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1.4.3. Regulation of the amount of dietary iron absorbed 
 
The amount of dietary iron absorbed by the body can be regulated in three ways.  ‘Mucosal 
block’ refers to a situation where the absorptive enterocytic cells are resistant to the 
absorption of additional iron due to the bodily intracellular quantities being met (Andrews, 
1999a, b).  An alternative mechanism for regulation is when the body-store iron levels are 
sensed and is termed ‘stores regulator’ (Finch, 1994). The stores regulator mechanism can 
influence the amount of dietary iron uptake under iron-deficient conditions, however, the 
exact molecular mechanisms involved in this process remains unknown.  The ‘erythropoietic 
regulator’, a third mechanism,  has the ability to increase the amount of iron that enters the 
body, independent of cellular iron levels, using a mechanism based on the amount of iron 
needed for erythropoiesis (Finch, 1994). 
 
Iron Transport 
 
1.4.4. Transferrin 
 
Transferrin is a plasma protein responsible for the transport of iron from the site of absorption 
to the places of utilization and storage.  The first step in transferrin mediated cellular iron 
uptake involves the binding of transferrin to transferrin receptor.  There are two types of 
transferrin receptors; each has its own tissue-specific and cell-specific expression pattern.  
The membrane bound glycoprotein, transferrin receptor 1, is expressed in all cells, excluding 
mature erythrocytes. Transferrin receptor 2 is expressed solely in the liver, more particularly 
in the hepatocytes.  Upon binding the transferrin receptor-transferrin-iron complexes are 
internalized and iron is released from the transferrin and enters the intracellular labile pool.  
Transferrin receptor-bound transferrin complexes are then recycled back to the cell surface 
for reuse in iron uptake (Lieu et al., 2001). 
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The transferrin molecule comprises of two globular domains with each domain containing a 
high-affinity binding site for a singular iron molecule (Fe3+). The transferrin molecule also 
possesses an affinity for the transportation of other metal ions; however, it has the highest 
affinity for the ferric iron.  The iron-transferrin kinship is pH dependent and iron is released 
from the transferrin molecule when the pH falls below 6.5 (Yang et al., 1984; Moos et al., 
2000).  Alternate forms of the transferrin molecule exist; namely apotransferrin (iron-free), 
monoferric (one iron molecule attached), diferric (two attached iron molecules).  The amount 
of each molecule present is dependent upon the concentration of iron and transferrin present 
in the blood plasma (Lieu et al., 2001). 
 
 
1.4.5. Transferrin receptor 1 
 
The transferrin receptor 1 homo-dimer has a molecular weight of 90 kDa and comprises two 
identical subunits.  Each monomer may be subdivided into three domains of which the third 
domain, the carboxyl-terminal ectodomain, is essential for transferrin binding (Buchegger et 
al., 1996; Lieu et al., 2001).  Each homo-dimer of the transferrin receptor contains a binding 
site for a transferrin molecule allowing two transferrin molecules to bind to a single receptor 
simultaneously.  The cytoplasmic portion of the transferrin receptor 1 molecule is required 
for endocytosis.  A conserved region located within the cytoplasmic portion of the receptor is 
responsible for an internalization signal allowing for highly efficient endocytosis of the 
receptor during iron uptake (Collawn et al., 1990, 1993).  Phosphorylation and 
dephosphorylation has been suggested to be the signals for internalisation, strengthened by 
the fact that treatment of tissues with protein phosphatase inhibitors results in an 85% 
reduction in the uptake of transferrin (Beauchamp and Woodman, 1994).  
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1.4.5.1. Expression of transferrin receptor 1 
 
Transferrin receptor 1 is expressed in all cells with the exception of mature erythrocytes; 
however, the levels of expression differ depending on the cell line.  Considering rapidly 
dividing cells; between 10 000 and 100 000 molecules per cell can be found expressed, 
whereas with non-proliferating cells the expression levels are low or virtually undetectable 
(Ioue et al., 1993).  The epithelial cells of a several organs express a basal level of transferrin 
receptor 1; however, rapidly dividing cells, the liver, placental tissue and erythrocytes have 
the highest level of expression.  High levels of iron are required for hemoglobin synthesis and 
cellular division explaining the high expression levels of transferrin receptor 1 expression 
(Ponka, 1999).  In non-erythroid cells transferrin receptor 1 is regulated post-transcriptionally 
by an interaction between iron regulatory proteins and iron responsive elements occurring in 
the 3’ untranslated region of its mRNA.  The 3’ region contains a string of five stem loop 
structures crucial for the iron mediated mRNA degradation.  In the event of low iron levels 
each of the iron responsive elements can be bound by one regulatory protein allowing for the 
stabilization of the transferrin receptor 1 molecule (Hentze and Kuhn, 1996; Klausner et al., 
1993).  Binding of the regulatory proteins blocks an endonuclease cleavage site, stabilizing 
the molecule and allowing for increased cell surface expression of the transferrin receptor 1 
glycoprotein.  The opposite is true in the event of high intracellular iron levels (Thompson et 
al., 1999).  The intracellular iron levels of erythroid cells do not have a major effect on the 
expression of transferrin receptor 1 mRNA as during erythroid differentiation the transferrin 
receptor 1 is regulated at a transcriptional level as oppose too post-transcriptionally (Chan et 
al., 1994).  It can therefore be concluded that the expression of transferrin receptor 1 is 
regulated by both transcriptional and post-transcriptional mechanisms. 
 
1.4.5.2. Transferrin receptor 1 function 
 
The cellular intake of iron from the plasma transferrin molecule is mediated by the binding of 
transferrin to transferrin receptor 1 on the cell surface.  The number of iron molecules bound 
to the transferrin protein affects its affinity for transferrin receptor 1: diferric transferrin has 
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the highest affinity and apotransferrin the lowest (Young et al., 1984).  A maximum of two 
transferrin molecules can be bound by a single transferrin receptor 1 protein at a time and 
therefore four iron atoms can be mediated at a time.  Tyrosine internalisation motifs located 
on the cytoplasmic portions of the transferrin receptor 1 molecule allows for high affinity 
binding to membrane bound adapter complexes.  The transferrin receptor-transferrin-iron 
complexes interact with these adapter complexes and are then internalised by the cells via an 
endocytic pathway.  Upon internalisation the endosome is acidified by means of an ATPase 
proton pump which allows for the release of the attached iron molecules.  The dissociation of 
the now apotransferrin from transferrin receptor 1 takes place at neutral pH at the cell surface 
recycling both the ligand and receptor for reuse (Lieu et al., 2001).  Released iron passes 
through the endosomal membrane via Nramp2 and is released into the cytoplasm.  The new 
acquired iron is either used for the synthesis of heme or is incorporated into iron containing 
molecules (Fleming et al., 1998). 
 
1.4.6. Transferrin receptor 2 
 
Transferrin receptor 2 is a type II transmembrane protein sharing 66% homology with 
transferrin receptor 1 in its extracellular domain (Kawabata et al., 1999).  It contains the 
internalisation motif YQRV, which is similar to that of transferrin receptor 1’s YTRF; 
however, upon sequence analysis of transferrin receptor 2 it is found that it possesses no iron 
responsive elements.  Transferrin receptor 2 is therefore not regulated by the iron regulatory 
protein-mediated feedback regulatory mechanism.  It is predominantly expressed in the liver, 
where transferrin receptor 1 levels are low.  Transferrin receptor 2 also possesses the ability 
to bind transferrin and its binding is pH dependent.    Transferrin receptor 2, however, differs 
from transferrin receptor 1 in its expression and regulation properties (Kawabata et al., 2000).  
Transferrin receptor 1 plays a role in general cellular uptake of iron, whereas transferrin 
receptor 2 is specifically involved in iron uptake and storage in the liver due to its high 
expression in hepatocytes. 
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1.4.7. Transferrin receptors in cancer onset 
 
The transferrin molecules supply the cells of the body with iron, therefore exhibiting a 
proliferative effect on these cells. In the context of this thesis the role transferrin, transferrin 
receptors and iron have in the growth of metastasizing tumour cells and a number of 
carcinoma lines can therefore be ascertained (Cavanaugh and Nicolson, 1990).  Cells 
exhibiting a low dependence on iron express low numbers of transferrin receptors on their 
cell surface, and when stimulated to proliferate will sequester an increase in the amount of 
transferrin receptors present to facilitate iron uptake (Seiser et al., 1993).  This theory is 
supported by numerous experiments, including the finding that anti-transferrin receptor 1 
antibodies can block lymphocyte activation and suppress the proliferation of tumour cells 
(Kemp et al., 1987); transferrin receptor 1 correlated with the proliferative response in 
metastatic breast cancer cells (Cavanaugh et al., 1999); and in a rat model expressing low 
amounts of rat transferrin receptor 1, the introduction and expression of human transferrin 
receptor 1 facilitates rat mammary adenocarcinoma cell line proliferation (Cavanaugh et al., 
1999). 
 
1.4.7.1. Transferrin-associated proteins 
 
1.4.7.1.1.  High iron gene (HFE) 
 
The HFE protein has been shown to be involved in the role of iron uptake due to its ability to 
associate with the transferrin receptor 1 protein.  The HFE and transferrin receptor 1 
molecules form a complex while within the endoplasmic reticulum, then make their way to 
the cell surface where they remain closely associated (Gross et al., 1998). The HFE gene 
codes for a 343-amino-acid protein belonging to the major histocompatibility complex class I 
family.  The protein is expressed in a wide variety of tissues at basal levels, with no 
expression occurring in brain tissue and the highest expression levels found in the liver and 
small intestine (Feder et al., 1996).  Interaction of the transferrin receptor 1 molecule with 
HFE results in a 5 – 10 fold reduction in the affinity of transferrin receptor 1 for transferrin 
Chapter 1: Literature Review 
15 
 
(Gross et al., 1998), and as a result the amount of transferrin-bound iron by cells and the 
build-up of intracellular iron levels are reduced under normal HFE expression conditions 
(Salter-Cid et al., 1999).  
 
1.4.7.2. Ceruloplasmin (CP) 
 
Ceruloplasmin is a copper-containing molecule responsible for the conversion of ferrous to 
ferric iron thus assisting in incorporating ferric iron into transferrin.  The primary site for 
ceruloplasmin production is the liver and synthesis is significantly increased during periods 
of iron deficiency (Lieu et al., 2001).   Due to the ferrioxidase activity of the ceruloplasmin 
protein it is crucial in the mobilization of iron from tissues and its incorporation into ferric 
transferrin, thereby preventing potentially damaging build-up of intracellular iron levels 
within tissues (Gitlin, 1998). 
 
 
1.5. Iron deficiency 
 
Deficiencies of iron is the most common cause of anemia, and with iron deficiency anemia 
the mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular 
hemoglobin concentrations are low.  Iron-deficient erythropoiesis is characterised by an 
increase in free erythrocyte protoporphyrin and microcytosis, indicated by mean corpuscular 
volumes of less than 83 femtoliters per cell.  Major cases of anemia under these conditions 
are iron deficiency anemia and anemia of chronic disease; where both cases have serum iron 
concentrations of less than 40 μg/dl and transferrin saturations of below 15 – 20% (Cook, 
1999).  Serum ferritin levels are found to be below 20 μg/l in iron deficiency anemia cases, 
and above 100 μg/l in anemia of chronic disease instances.  Serum transferrin receptor 1 
levels are calculated using the transferrin receptor 1-ferritin index, where the normal range is 
0.076 (±0.062 SD) and in iron deficiency cases values around 3.739 (±3.413 SD) are obtained 
(Punnonen et al., 1997). 
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1.6. Iron overload 
 
In instances of suspected iron overload the serum iron concentration, transferrin saturation 
and serum ferritin levels should be measured.  Serum iron concentration levels above 20 μM, 
transferrin saturation greater than 50 – 60% and serum ferritin levels greater than 400 μg/l are 
typical of iron overload presenting patients (Mura et al., 2000).  Serum transferrin levels are 
considered to be early indications of hemochromatosis with transferrin saturation levels 
higher than 45% occurring in 98% of cases, however, serum ferritin levels are a more 
accurate depiction of iron accumulation.  Raised serum ferritin levels are also symptomatic of 
conditions not associated with increased iron levels, and this need be considered in diagnosis 
(Lieu et al., 2001). 
The accumulation of iron in the liver is most commonly assessed using liver biopsy and 
provides information on iron content, iron distribution within tissues and an indication of 
cirrhosis.  The hepatic iron index is used to assess the iron load of the liver, and 
measurements suggesting iron overload are obtained following to genetic testing which may 
be performed to investigate the genetic component(s) involved (Lieu et al., 2001). 
 
1.7. The HAMP gene 
 
The 25 amino acid protein, hepcidin, encoded for by the HAMP gene is initially synthesised 
as an 84 amino acid peptide, which then undergoes processing steps in order to form the 
aforementioned iron regulatory molecule.  The 25 amino acid hepcidin molecule comprises 
of four intra-chain disulphide bonds, eight cysteine residues and is also a member of the 
defensin family of molecules (Luft, 2004).  These molecules are involved in innate immunity 
highlighting the initial role hepcidin was believed to have played.  However, despite the 
structural similarity of the hepcidin protein to many antimicrobial peptides and its sequence 
conservation amongst many vertebrate species, it is doubtful that the hepcidin protein is 
produced in humans for its antifungal or antibacterial properties (Krause et al., 2000).  This 
theory is strengthened by the low urinary concentrations detected. 
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1.7.1. Foundation for hypotheses of gene function 
 
Many animal models, using transgenic mice lines (Nicolas et al., 2001), have allowed for the 
elucidation of the hepcidin protein in playing a vital role in the regulation of iron metabolism.  
Experiments by Atanasiu et al., (2006) revealed that the hepcidin protein is involved in the 
inhibition of the intestinal absorption of iron, induction of iron sequestration in macrophages 
and the blockage of iron transport across the placental barrier.  In essence, the hepcidin 
protein is up regulated in response to high bodily iron levels, preventing any further 
assimilation of dietary iron in the intestinal lumen.  This theory is further strengthened by the 
fact that hepatic hepcidin levels appear lowered during processes such as erythropoiesis, 
allowing for increased uptake of iron in the intestinal lumen as well as the release of iron 
from macrophage cells.  Iron is crucial to the erythropoietic process making its increased 
availability of the utmost importance. 
In contrast to this, increased hepcidin levels are observed in cases of inflammation or iron 
overload.  The increased level prevents any further iron assimilation at the intestinal lumen 
and also stimulates the sequestering of iron by macrophage cells making this crucial resource 
unavailable to invading pathogens.  These scenarios clearly emphasize the hepcidin dual role 
in both regulating the homeostatic balance or iron as well as its involvement in innate 
immunity (Deicher and Horl, 2006). 
The transcription products of the HAMP gene can be found in liver, muscle, intestinal, 
stomach, heart and lung tissues; but, its primary location is in liver tissue.  Under normal 
circumstances it is the natural response of the body to increase the amount of hepcidin 
produced in response to elevated iron levels or iron overload; but, the exact mechanism 
allowing for this increase remains obscure.  This is partly reasoned for by the fact that no iron 
response element binding regions have been located in the HAMP gene itself and therefore up 
and down regulation of the aforementioned gene must be taking place by methods other than 
direct interaction with iron regulatory binding proteins (Atanasiu et al., 2006).   
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1.7.2. Proposed mechanisms of protein function 
 
Ferroportin (FPN), expressed on the cell surface of hepatocytes, macrophages and intestinal 
enterocytes is the only known mammalian exporter of iron and a believed molecular target of 
the hepcidin protein (Nemeth et al., 2004).  Upon hepcidin binding, the FPN molecule is 
subsequently internalised and degraded preventing any further iron export (Figure 1.1).  In 
the event of iron shortage hepcidin levels are reduced, FPN expressed and iron can be 
released from iron stores to plasma transferrin and transported to the requiring tissue sites 
(Atanasiu et al., 2006). 
An alternative mechanism of function is that the liver is able to detect the body iron status by 
the amount of transferrin-bound iron via its receptor transferrin receptor 2.  Monitored 
increased uptake subsequently results in the up-regulation of the HAMP gene and increase in 
the amount of hepcidin protein produced.  Hepcidin associates with the β2-microglobulin – 
HFE – transferrin receptor 1 complex, increases iron uptake in the duodenal crypt cells and 
increases iron retention by reticulo-endothelial macrophages.  As the crypt cells then mature 
they are programmed to express lesser amounts of iron transport proteins and therefore allow 
for reduced uptake of dietary iron (Luft, 2004; Leong and Lonnerdal, 2004). 
 
1.8. Oesophageal cancer (OC) 
 
Worldwide, oesophageal cancer (OC) is the sixth leading cause of cancer related deaths 
(Pisani et al., 1999).  More than 90% of OC are either squamous-cell carcinomas (SCC) or 
adenocarcinoma (ADC), with three quarters of all ADC being found in the distal end of the 
oesophagus and squamous prevalence evenly spread between the middle and lower third of 
the oesophagus (Siewert et al., 2001).  The exact mechanisms of disease pathogenesis remain 
unclear; however, irritation of the oesophagus by oxidative damage resulting from smoking 
or gastroesophageal reflux causing inflammation of the oesophageal tissues, may initiate the 
carcinogenic process (Terry et al., 2000).  Once developed, the disease has the ability to 
spread quite rapidly and 14 – 21% of submucosal cancers, or T1 lesions, as well as 38 – 60 % 
of muscle-invading cancers, T2 lesions, associated with spread to the lymph nodes.  At the 
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time of diagnosis more than 50% of patients have already radiographically detectable 
metastases (Siewert et al., 2001; Collard et al., 2001).  Etiological focuses indicated that the 
OC risk is directly correlated to the amount of cigarettes smoked per day and the duration of 
smoking.  Smoking brings tobacco carcinogens, in particular nitrosamines, in contact with the 
oesophageal tissue causing irritation (Wu et al., 2001). 
 
1.8.1. Squamous cell carcinoma (SCC) 
 
Chronic irritation of the oesophageal mucosa is associated with increased risk for squamous-
cell carcinoma development, with alcohol consumptions, smoking, and the combination of 
the two greatly increasing the risk for SCC development.  Achalasia and oesophageal 
diverticuli, cases in which bacteria decomposes trapped food within the oesophagus, have 
also been associated with increased risk for squamous-cell carcinoma development due to the 
toxins and irritants released by the aforementioned bacteria present (Wu et al., 2001; Sandler 
et al., 1995; Avisar and Luketich, 2000).   
 
1.8.2. Adenocarcinoma (ADC) 
 
Patients suffering from chronic gastroesophageal reflux have an eight-fold increase in risk for 
developing adenocarcinoma (Lagergren et al., 1999).  Barrett’s oesophagus is characterised 
by the replacement of stratified epithelial cells of the distal oesophagus with specialised 
columnar epithelium which is typically seen in the stomach or intestine.  The transformation 
of this columnar epithelium into areas of dysplasia is a result of mutation development within 
this tissue, putting individuals with Barrett’s oesophagus at high risk for adenocarcinoma 
development (Shaheen and Ransohoff, 2002).  The genetic explorations characterizing the 
development of Barrett’s oesophagus reveal chromosomal losses in chromosomes 4, 5, 9 and 
18; chromosomal gains in chromosomes 8, 17 and 20; however, efforts to match these 
chromosomal aberrations to specific genes remain largely elusive (Walch et al., 2000; 
Wijnhoven et al., 2001). 
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1.9. Iron and cancer 
 
Iron-containing enzymes are crucial for the catalization of numerous reactions key to the 
effective and efficient progression of DNA synthesis and energy provisions.  As previously 
discussed, iron is transported in the serum bound to transferrin and subsequently binds to the 
membrane bound transferrin receptor 1 and is internalised.  Cancer cells have been shown to 
contain higher amounts of transferrin receptor 1 than normal and therefore allow for a higher 
level of iron uptake (Larrick and Cresswell, 1979; Chitambar et al., 1983).  Radiolocalisation 
using 67Ga, which binds to the transferrin-iron binding site and is subsequently delivered to 
the transferrin receptor 1, demonstrates the increased cellular iron uptake described (Chan et 
al., 1987).  Strengthening the fact that iron is an essential component of cellular proliferation 
is that the use of iron chelators, such as desferrioxamine, inhibit the growth of aggressive 
tumours both in vivo and in vitro, highlighting the dependence of tumour tissue on this trace 
element (Kwok and Richardson, 2002).   
Taking the body’s natural defense mechanisms into account, the dependence of tumour cells 
on iron is further demonstrated.  Macrophage cells produce nitrogen monoxide (NO), when 
activated, comes in contact with a variety of iron containing molecules involved in energy 
metabolism and DNA synthesis.  NO is able to inhibit the uptake of iron from  transferrin due 
to its effect on the inhibition of ATP production as well as the mobilisation of iron from 
tumour cells in both the presence and absence of activated macrophages (Wardrop et al., 
2000; Richardson et al., 1995; Watts and Richardson, 2000).  
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1.9.1. Neoplastic cells 
 
The mechanisms for iron uptake, storage and utilisation appear to be similar for both normal 
and neoplastic cells, however, there are several molecules identified in neoplastic tissues that 
could play a role in iron acquisition. 
 
1.9.1.1. Transferrin 
 
The major iron transport protein in the blood serum is the glycoprotein, transferrin.  Due to 
the iron-binding properties of this molecule it is an essential growth factor required for all 
cells in a proliferating state (Morgan, 1981; Richardson and Ponka, 1997).   
The MCF-7 human breast cancer cell line has been shown to secrete a factor 
immunologically identical to transferrin which may act as an autocrine growth factor.  This 
could bestow a selective advantage facilitating the growth of the rapidly dividing tumour 
cells in poorly vascularised areas (Vandewalle et al., 1989).  Other cancer cells lines have 
also been shown to secrete transferrin, including small cell carcinoma and T-lymphoma cells 
(Vostrejs et al., 1988; Morrone et al., 1988). 
 
 
1.9.1.2. Melanotransferrin 
 
Melanotransferrin is a homologue of the transferrin molecule, but, membrane bound.  
Melanotransferrin is generally not expressed, or expressed at relatively low levels within 
normal tissue; however, in tumour cells (especially melanoma cells) and fetal tissues, 
expression is observed at much higher levels (Woodbury et al., 1980; Brown et al., 1982).  
Although promising at first, recent studies performed have indicated the melanotransferrin 
protein in not vital for obtaining iron for proliferating neoplastic cells lines even though an N-
terminal iron binding site has been identified within it (Richardson and Baker, 1990; 
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Richardson and Ponka, 1997).  Its involvement in iron metabolism cannot be completely 
ruled out, but further studies are warranted to elucidate the exact function of this molecule.  
 
1.9.1.3. Ceruloplasmin 
 
Ceruloplasmin is a multi-copper oxidase responsible for the conversion of ferrous iron to 
ferric iron, enabling iron mobilization from the bodily tissues (Kaplan and O’Halloran, 1996).  
In a study by Mukhopadhyay et al. (1998) 55Fe was shown to be taken up from 55Fe-
nitrilotriacetate, and this was mediated by ceruloplasmin.  Non-physiologically relevant 
temperature and Fe-complexes were used and therefore this experiment was appropriately 
replicated (Richardson, 1999).  This experiment showed ceruloplasmin to be necessary for 
the efflux of iron from cells, but eliminated its role in iron uptake in cancerous cell lines. 
 
1.9.2. Ferritin and neoplastic cells 
 
Serum ferritin levels are increased in patients suffering from several forms of neoplasia, 
suggesting a relationship between ferritin and cancer (Marcus and Zinberg, 1975; Hann et al., 
1980).  An autocrine growth factor secreted by human leukemia cells has been shown to have 
an immunological identity with the ferritin molecule and an antibody to ferritin inhibited the 
growth of these cells (Kikyo et al., 1994).   Ferritin binding sites as well as the endocytosis of 
ferritin has been observed in neoplastic cells (Bretscher and Thompson, 1983).  Evidence to 
suggest altered ferritin expression in cancer cells also exists but all in all further research 
needs to be performed in order to obtain a greater insight in the exact role ferritin could play 
in neoplastic cell proliferation. 
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1.10. TP53 
 
p53, a tumour suppressor protein, is coded for on the p-arm of chromosome 17.   Its loss of 
function has been associated with the development of several forms of cancer (Montesano et 
al., 1996).  Allelic loss on chromosome 17p has been specifically associated with OC.  
Studies show that in the case of OC, p53 mutation in one allele (in cells pertaining two 17p 
alleles) is an early event in the development of oesophageal carcinogenesis.  This suggests 
the aberrant p53 protein exerts a dominant effect that is able to abolish the effects of the 
remaining wild-type p53 allele coding protein (Huang et al., 1993; Maesawa et al., 1994).  
The presence of one mutation may then favour a deletion in the other allele at a later stage 
(Montesano et al., 1996). 
 
1.10.1.  TP53 and carcinogenesis 
 
The TP53 gene codes for a 53 kDa phosphoprotein, containing sequence specific DNA 
binding properties, a protein with a very short half-life preventing build-up despite constant 
synthesis.  Mutations occurring within the TP53 gene are also amongst the most common 
human cancer related genetic abnormalities (Hollstein et al., 1996).  In the event of DNA 
damage the p53 protein is stabilised, extending its half-life, allowing for it to exert an effect 
on the many gene targets it interacts with.  Some of these gene targets are responsible for cell 
cycle arrest and apoptosis (Kastan et al., 1991; Tishler et al., 1993).  p53 therefore functions 
to prevent the replication of damaged DNA by either arresting the cell cycle or by initiating 
apoptosis.  Mutations occurring in TP53 which have been linked to human cancers are 
thought to disrupt the DNA binding domain of the p53 protein preventing the activation of its 
target genes.  This facilitates the replication of damaged DNA and subsequently could allow 
for the accumulation of the genetic aberrations necessary to result in a cancerous phenotype 
(Cho et al., 1994).  Further hypotheses suggest mutant TP53 to have tumour promoter 
properties, founded by the maintenance of high levels of p53 within cancer tissues.  This 
indicates that the cancer cells are selecting for mutant TP53 expression.  The exact 
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mechanisms for this selection are, however, unknown and further research need be carried 
out to elucidate the exact mechanisms (Hainaut, 1995). 
The literature exploring the occurrence of TP53 mutations in oesophageal cancer is extensive.  
Considering 240 cases of squamous-cell carcinoma, 45.8 % were found to contain mutations 
within p53, with the prevalence considering adenocarcinoma being even higher with 71.8 % 
of all cases including aberrant versions of the gene (Montesano et al., 1996).  The majority of 
mutations are found to be located within exons 5 – 8 of the 11 exons coding for the gene.  
Exons 5 – 8 are responsible for encoding the entire DNA-binding domain of the p53 protein 
including its flanking regions, with mutations occurring outside of this region being 
uncommon in oesophageal cancer associations (Wagata et al., 1993). 
Immunohistochemical staining reveals that the p53 protein is expressed in normal 
oesophageal cells and at heightened levels in the nuclei of proliferating ones (Bennett et al., 
1992).  The protein detected, however, may be representative of mutant p53 protein or the 
functionally active wild-type protein possessing the ability to suppress the replication of cells 
containing damaged DNA (Hainaut, 1995). 
 
1.10.1.1. The distribution of TP53 mutations in OC 
 
The distribution and occurrence of TP53 mutations are different for the different types of OC, 
namely squamous-cell carcinoma and adenocarcinoma.  In adenocarcinoma, mutations are 
predominantly located within exons 5 – 8 with mutational hot spots at codon 175 in exon 5 
and codons 248 and 273 in exon 8 (Hollstein et al., 1996).   Codon 175 is also found to be 
frequently mutated in squamous-cell carcinoma; however, it is the relatively high levels of 
mutation attributed to codons 193, 194 and 195 that give squamous-cell carcinoma its 
characteristic TP53 mutation profile.  This specific mutation profile is not found to match any 
other form of cancer to date, in contrast the three exons discussed for adenocarcinoma being 
the most frequently mutated codons in all cancers (Hollstein et al., 1996).  The majority of 
the p53 mutations identified occur in a region encoding for the DNA-binding domain of the 
protein; mutations disrupting the core domain are rare.  In squamous-cell carcinoma, 
however, the majority of mutations identified appear to disrupt the hydrophobic core of the 
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p53 protein and are believed to disrupt regions usually in the tertiary structure of the wild-
type protein molecule.  These kinds of mutations are most likely to be particularly disruptive 
(Montesano et al., 1996). 
Mutated p53 sequence may be as result of endogenous circumstances, or as result of exposure 
to exogenous or environmental carcinogens.  The type of p53 mutations present may allow 
for insight into the mechanisms responsible for the DNA aberrations driving the 
tumourigenesis process, meaning that analyzing the spectrum of p53 mutations can be useful 
in identifying the carcinogens involved in the etiopathogenesis of OC (Hollstein et al., 1996).  
Mutations of p53 associated with adenocarcinoma show highest frequency of transition at 
CpG dinucleotides (69 %).  CpG transitions are less frequent in squamous-cell carcinoma 
with mutations at A: T bp being most frequent.  This indicates that TP53 mutations associated 
with squamous-cell carcinoma is most likely a result of exposure to exogenous carcinogens 
(Hollstein et al., 1996; Montesano et al., 1996).  
It is therefore apparent that TP53 gene mutations play a critical role in the development 
and/or progression of both the squamous-cell carcinoma and adenocarcinoma forms of OC, 
despite the two forms having distinct pathological entities at a molecular level.  The two 
forms of cancer are also distinct in terms of the frequency, type and distribution of the p53 
mutations they possess indicating the diverseness of aberration that can lead to disease.  Due 
to the highly conserved DNA-binding domain of the p53 protein, mutation of the regions 
interacting with this molecule could produce the same effects as mutations altering p53 
protein function.  Further studies exploring this and p53 protein aberration could prove 
particularly rewarding to our understanding of carcinogenesis, especially considering the fact 
that heightened p53 expression levels have been reported in the nuclei of proliferating cells. 
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1.11. Study objectives 
 
Our research group has its focus on a number of genes involved in iron metabolism in the OC 
patient and control cohorts used in this study.  The genes include HFE (see section 1.4.7.1.1), 
SLC40A1 (see section 1.4.2), CP (see section 1.4.7.2), HAMP (see section 1.7) and HEPH 
(see section 1.9.1.3). The HAMP gene has recently been identified to be a crucial regulator in 
iron metabolism and has been associated with a variety of iron related disorders, cancer 
included.  The promoter region of the HAMP gene has yet to be characterized, and therefore 
the focus of this study was the characterization of the 5’ UTR of the HAMP gene in an OC 
cohort. 
 
The objectives of this study were as follows:- 
1. Identification of novel and previously identified promoter variants in the HAMP gene 
of an OC patient cohort. 
2. Investigation of the effects of the identified variants in the promoter region of HAMP 
on gene expression. 
3. Investigation of the iron parameters of an OC cohort relative to a healthy control 
population and the effect that the presence of a promoter variant in the HAMP gene 
may have on these parameters. 
4. Assessment of the genotype-phenotype correlation between variant presence and 
absence, OC presentation and iron parameter indicators. 
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The study protocol was approved by the Ethics Review Committee of the University of 
Stellenbosch (N07/06/147) 
2. Detailed Experimental Procedures 
 
2.1. Subjects 
 
The patient study population comprised 48 unrelated individuals of the Black Xhosa-
speaking population of South Africa.  Individuals were from the Transkei region of Southern 
Africa with cultural habits originating from Xhosa tribes. 
Written and informed consent was obtained from each participating individual before 
obtaining blood samples.  Blood samples were obtained from the 48 unrelated patients, all of 
which suffered from squamous cell carcinoma of the eosophagus.  A barium swallow 
followed by theatre biopsies were performed on patients to confirm the presence of ADC or 
SCC on a histological basis (Hermanek and Sobin, 1987). 
Following written and informed consent, blood samples were obtained from 51 healthy, 
unrelated population and sex matched individuals to serve as a control cohort.  Brush biopsy, 
using a Nabeya capsule, was used for early screening of OC amongst the control individuals. 
Iron overload could be classified under the following conditions:  transferrin saturation 
greater than 45% and/ or serum ferritin exceeding 200µg/l in females and 300µg/l in males.  
The following iron parameters were obtained for all participating patient and control 
individuals: serum-iron, transferrin, transferrin saturations, ferritin, Alanine Transaminase 
(ALT) and C-reactive protein (CRP) levels.  Transferrin saturation was determined on the 
basis of serum transferrin and serum iron concentrations.  ALT and CRP levels were taken to 
differentiate between raised serum ferritin levels due to increased body iron stores or 
hepatocellular damage and inflammation respectively.  Normal serum-iron ranges for males 
and females are 65 - 176µg/dL and 50 – 170µg/dL, respectively. Transferrin levels of 
between 0.21g/L to 0.36g/L are considered within the normal range for healthy adults.  ALT 
reference ranges lie between 5 and 40 IU/L for healthy adults, with CRP reference ranges for 
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healthy adults of 10 – 40mg/L indicating mild inflammation and viral infection, 40 – 200 
mg/L indicating active  bacterial infection and >200mg/L indicating severe bacterial 
infection. 
 
2.2. Polymerase chain reaction (PCR) amplification 
 
2.2.1. Oligonucleotide primers 
 
The primer pairs, melting temperatures and PCR conditions used for the amplification of the 
HAMP promoter region (1202bp) are shown in Table 2.1.  Primers were designed using the 
Primer 3 program (Rozen and Skaletsky, 2000, available at 
http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi,2002).  Similar parameters 
are shown for the amplification of the TP53 gene (Table 2.2).  These primer pairs were 
adapted, and modified from Audrezet et al. (1993). 
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Table 2.1 Oligonucleotide primers used for the amplification of the HAMP promoter region 
Primer 
name 
Primer Sequences  
5’ – 3’ 
Tm  
(⁰C) 
Amplicon size 
(bp) 
TA1 TA2 PCR 
cycle 
MgCl2 
[mM] 
PP2F CATCGGACTGTAGATGTTAGC  60 256 60  A 1.5 
PP2R TCAAGACTAGCCTGGGCAAC  62 
PP3F CACGCCTGGCTAAATTTGTT  58 326 55  A 2 
PP3R CACCACACGTGCATAGGTTC  62 
PP4F TCAAGGGTCTGACACTGGG  62 312 60 55 B 1.5 
PP4R CCATCACGATGTCATTCTGC  60 
PP5F AAGTGAGTGGAGGAGAGCG  62 285 55  A 2 
PP5R CTTTGCTCTGTCTCATTTCC  58 
PP6F CTGAGGGTGACACAACCCT  60 291 56  A 1 
PP6R AGAGCCACTGGTCAGGCTG  62 
Abbreviations: 5’, 5-prime; 3’, 3-prime; ⁰C, degrees Celcius; bp, base pair; F, Forward; mM, millimoles per 
liter; MgCl2, magnesium chloride; PCR, polymerase chain reaction; PP, promoter primer; R, Reverse; TA1, 
annealing temperature one; TA2, annealing temperature two; Tm, melting temperature [Tm = 2(nA + nT) + 4(nG + 
nC)]. (For A and B cycles refer to section 2.2.2) 
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Table 2.2 Oligonucleotide primers used for the amplification of TP53 
Primer 
name 
Primer Sequences  
5’ – 3’ 
Tm  
(⁰C) 
TA1 TA2 PCR 
cycle 
MgCl2 
[mM] 
Ex2F GGTTGGAAGTGTCTCATGCTGGAT  59.1 Not optimized 
Ex2R GACAAGAGCAGAAAGTCAGTCCCA  58.7 
Ex2-4F CAGGTGACCCAGGGTTGGAAG  60.1 50 54 B 1.5 
Ex2-4R GGAAGGGACAGAAGATGACAG  54.8 
Ex4F CCAGCAGCTCCTACACCGGC  63.1 55          A 2 
Ex4R GAATCCCAAAGTTCCAAACA  50.9 
Ex5aF CTTTCAACTCTGTCTCCTTC  50.3 55          A 2 
Ex5aR CCTGGGCAACCAGCCCTGTC  63.6 
Ex5bF TGGCCAAGACCTGCCCTGTG  62.7 55          A 2 
Ex5bR CCTGGGCAACCAGCCCTGTGGT  66.5 
Ex6F TACAAGCAGTCACAGCACATGACG  59.4 Not optimized 
Ex6R AGGGAGGTCAAATAAGCAGCAGGA  60.1 
Ex7F TTGCCACAGGTCTCCCCAAG  59.8 54 50 B 1.5 
Ex7R GGGCACAGCAGGCCAGTGTG  64.1 
Ex8F GGACAGGTAGGACCTGATTTC  54.6 55              A 2 
Ex8R AATCTGAGGCATAACTGCAC  52.8 
Abbreviations: 5’, 5-prime; 3’, 3-prime; ⁰C, degrees Celcius; bp, base pair; Ex, exon; F, Forward; mM, 
millimoles per liter; MgCl2, magnesium chloride; PCR, polymerase chain reaction; R, Reverse; TA1, annealing 
temperature one; TA2, annealing temperature two; Tm, melting temperature [Tm = 2(nA + nT) + 4(nG + nC)]. (For 
A and B cycles refer to section 2.2.2) 
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2.2.2. PCR amplification reactions and conditions 
 
PCR reactions were performed in 25μl volumes, using the primer pairs listed in Table 2.1 and 
2.2.  The reactions comprised of 20ng DNA template, 0.2mM of each dNTP (dATP, dCTP, 
dGTP, dTTP) (Fermentas), 10pmol of each primer, 1 x Taq buffer (Bioline), MgCl2 (Bioline) 
at concentrations indicated in Table 2.1 and 2.2, and 0.5U Taq polymerase enzyme (Bioline).  
Two different PCR cycling programs were used for amplification, labeled A and B: 
 
Cycle A 
An initial denaturation step at 95⁰C for 5 minutes, followed by 35 cycles of denaturation at 
95⁰C for 30 seconds, 45 seconds at the annealing temperature specified in Table 2.1 or 2.2 
(indicated as TA1), and 30 seconds of extension at 72⁰C.  This was followed by a final 
extension time of 10 minutes at 72⁰C. 
Cycle B 
An initial denaturation step at 95⁰C for 5 minutes, followed by 10 cycles of denaturation at 
95⁰C for 30 seconds, 45 seconds at the annealing temperature specified in Table 2.1 or 2.2 
(indicated as TA1), and 30 seconds of extension at 72⁰C. This was followed by 30 cycles of 
denaturation at 95⁰C, 45 seconds at the annealing temperature specified in Table 2.1 or 2.2 
(indicated as TA2), and 30 seconds of extension at 72⁰C.  A final extension time of 10 minutes 
at 72⁰C was then allowed. 
 
2.3. Agarose gel electrophoresis 
 
PCR amplification success was tested on a 1.5% (w/v) horizontal agarose gel [2.25g agarose 
in 150ml 1 x TBE (90mM Tris-HCl, 90mM H3BO3 and 0.1mM EDTA, pH 8.0) and 0.01% 
(v/v) ethidium bromide (EtBr)].  Prior to loading, 5μl of the PCR product was mixed with an 
equal volume of cresol red loading buffer (2mg/ml cresol red and 35% (w/v) sucrose) and 
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loaded onto the gel.  A 100 bp ladder (Fermentas) was used as a molecular size marker in 
order to assess whether the size of the amplicon obtained was correct.  The PCR products 
were resolved at 120V for one hour in 1 x TBE buffer solution and the DNA subsequently 
visualized by ultraviolet light transillumination assisted by a GeneSnap MultiGenius Bio 
Imaging System (Syngene). 
  
2.4. Heteroduplex single stranded conformational polymorphism (HEX-SSCP) 
analysis 
 
A 30cm vertical gel apparatus was used for HEX-SSCP analysis and samples were loaded on 
30cm 12% polyacrylamide (PAA) gels [7.5% urea, 1.5 x TBE (135mM Tris-HCl, 90mM 
H3BO3 and 2mM EDTA, pH 8.0), 12% (w/v) PAA (1% C of a 40% stock (99 acrylamide (A): 
1 bisacrylamide (BAA)), 0.1% (w/v) ammonium persulphate (APS) and 0.01% N, N, N’, N’ 
– tetramethylethylenediamine (TEMED)].   
Prior to loading, PCR product was mixed with 15μl bromophenol blue loading dye (95% 
(v/v) formamide, 20mM EDTA, 0.05% (w/v) bromophenol blue and 0.05% (w/v) Xylene 
cyanol) and denatured at 95ºC for a duration of 10 minutes.  Immediately after the 
denaturation step, tubes were snap cooled by incubation on ice for a period of 5 minutes. 
Gels were electrophoresed at 250V for 18 hours at 4ºC in 1.5 x TBE buffer.  Upon 
completion, gels were stained by submerging in a 0.01% (v/v) ethidium bromide solution by 
submergence therein for 10 minutes and subsequently de-stained in dH2O for 5 minutes.  
Visualisation was performed using ultraviolet light trans-illumination [MultiGenius Bio 
Imaging System (Syngene)].  
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2.5. Semi-automated DNA sequencing analysis 
 
PCR products showing aberrant conformers upon HEX-SSCP analysis were reamplified and 
sent to InQaba Biotec for bi-directional semi-automated sequencing analysis.  The primers 
used for sequencing are the same as those used for PCR amplification in Tables 2.1 and 2.2.  
Sequencing results were then subsequently analyzed using ClustalW and BioEdit Sequence 
Alignment Editor software (Hall, 1999 and Thompson et al., 1997).  
 
2.6. Construct preparation 
 
Primer sets PP2, PP3, PP4 and PP5, outlined in Table 2.1, were modified to contain 
restriction enzyme recognition sites for the NheI (G*CTAG C) and BglII (A*GATC T) 
endonucleases (Table 2.3).  Variants identified in the promoter region of the HAMP gene; 
namely -429 G/T, -582 A/G, and -188 C/T were amplified using the primers and reaction 
conditions specified in Table 2.3.  These products were then purified according to procedures 
outlined in section 2.6.1 and the purified PCR product obtained was subsequently used for 
construct preparation. 
The pGL4.10[luc2] (Promega) promoterless vector was used for preparation of constructs 
containing the entire HAMP promoter region.  This was performed for the -429 G/T and -582 
A/G variants only.  The pGL4.23[luc2/minP] (Promega) minimal promoter-containing vector 
was used for the preparation of the constructs with fragments of the HAMP promoter 
containing the variant under investigation and flanking regions of +/- 200bp.  This was 
performed for the -188 C/T, -429 G/T and -582 A/G variants.  A whole promoter-containing 
construct could not be prepared for the -188 C/T fragment due to the occurrence of other 
variants within the vicinity of the variant of interest.  Proliferation of a β-galactosidase 
(Promega) producing plasmid was performed for co-transfection with the promoter-less 
pGL4 constructs for normalization of the firefly luciferase readings obtained.  Proliferation of 
the pGL4.73[hRluc/SV40] (Promega) vector producing renilla luciferase protein was used for 
co-transfection with the minimal promoter-containing constructs for normalization of the 
firefly luciferase readings obtained. 
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Table 2.3 Oligonucleotide primers used for the incorporation of endonuclease recognition sites 
Primer 
name 
Primer Sequences  
5’ – 3’ 
Tm  
(⁰C) 
TA1 TA2 PCR 
cycle 
MgCl2 
[mM] 
PP2F AGTGCTAGCCATCGGACTGTAGATGTTA  62 60  A 2 
PP6R AGAGCCACTGGTCAGGCTG  62 
PP3F AGTGCTAGCCACGCCTGGCTAAATTTGTT  64 55  A 2 
PP3R TGAAGATCTCACCACACGTGCATAGGTT  61 
PP4F AGTGCTAGCTCAAGGGTCTGACACTGGG  65 60 55 B 1.5 
PP4R TGAAGATCTCCATCACGATGTCATTCTGC  60 
PP5F AGTGCTAGCAAGTGAGTGGAGGAGAGCC  65 55  A 2 
PP5R TGAAGATCTCTTTGCTCTGTCTCATTTCC  59 
Abbreviations: 5’, 5-prime; 3’, 3-prime; ⁰C, degrees Celcius; bp, base pair; F, Forward; mM, millimoles per 
liter; MgCl2, magnesium chloride; PCR, polymerase chain reaction; PP, promoter primer; R, Reverse; TA1, 
annealing temperature one; TA2, annealing temperature two; Tm, melting temperature [Tm = 2(nA + nT) + 4(nG + 
nC)]. 
 
2.6.1. Purification of DNA solutions 
 
Purification of DNA solutions was performed using the GFX PCR DNA and Gel Band 
Purification Kit (Amersham Biosciences – GE Healthcare).  A GFX column was placed 
within a collection tube for each purification to be performed and 500μl Capture Buffer 
(Amersham Biosciences: containing acetate and choatrope) added to each GFX column.  The 
DNA solution to be purified was then added to the Capture Buffer and mixed thoroughly via 
pipetting action.   Post a 30 second centrifugation step at 16000 x g, the elute was discarded.  
A mixture of 500μl Wash Buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA, absolute ethanol to 
a final concentration of 80%) was subsequently added to the GFX column and subjected to 
centrifugation at 16000 x gravity for 30 seconds.  The flow-through was discarded and the 
GFX column transferred to a clean 1.5ml Eppendorff tube.  A volume of 50μl elution buffer 
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(10mM Tris-HCl, pH 8.0) was added and each column and subjected to a 1 minute 
centrifugation step at 16000 x gravity. 
 
2.6.2. Digestion 
 
The PCR product, pGL4.10 and pGL4.23 vectors were digested with restriction enzyme 
endonucleases NheI and BglII (NEB) allowing for the creation of sticky ends for ligation.  
The multiple cloning sites of pGL4 vectors include recognition sites for the aforementioned 
restriction endonucleases, allowing for insert incorporation in a specific orientation only. 
The digestion of the PCR products and pGL4 vectors were performed in 20µl reactions, 
consisting of 10µl PCR product, 2U or the relevant enzymes (NheI and BglII) and 1X buffer, 
in a 37ᵒC waterbath, and digested overnight. 
 
2.6.3. Ligation and dephosphorylation 
 
Dephosphorylation of the digested pGL4 vectors used, and ligation of the HAMP promoter 
inserts and the dephosphorylated vector, was carried out using the Rapid DNA Dephos & 
Ligation Kit (Roche).  Dephosphorylation and ligation were carried out according to the 
manufacturer’s specifications where rAPid Alkaline Phosphatase and T4 DNA Ligase were 
used for dephosphorylation and ligation, respectively. 
 
2.6.4. Test ligation 
 
To test for successful ligation the ligated product and insert-less pGL4 vector was 
subsequently digested using only the NheI enzyme.  The digested products were resolved on 
a 1% Agarose gel as specified in 2.3.  Restriction enzyme digestion reactions were carried out 
using the same protocols outlined in section 2.6.2. 
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2.7. Transformation 
 
The competent cell transformation procedure was performed using the EZ Competent cells 
(Qiagen) kit.  A volume of 4μl of ligation mixture (as outlined in section 2.6.3) was added to 
pre-cooled tubes containing 25μl of Qiagen EZ Competent cells, and subsequently incubated 
on ice for 30 minutes.  This was followed by a heat shock step at 42⁰C for 30 seconds, 
followed by incubation on ice for 2 minutes.    Luria-Bertani (LB) (10g NaCl, 10g Tryptone, 
5g Yeast Extract, brought to volume of 1L) medium (300 μl) was added to each tube and 
incubated on a shaker at 37⁰C, shaking at 180rpm for one hour. Following an overnight 
incubation at 37ᵒ C,  150μl culture was plated out on LB-Agar-Ampicillin (10g NaCl, 10g 
Tryptone, 5g Yeast Extract, 20g Agar brought to volume of 1L, with 0.06mg/ml ampicillin) 
plates and incubated overnight at 37⁰C.   
 
2.8. Colony PCR 
 
Colony PCR was performed on the colonies obtained in order to verify the presence and 
orientation of the insert.  PCR reactions were performed using the primers and reaction 
conditions outlined in Table 2.4.  The RV3 primer was specific to the pGL4 vector used.  
When used in conjunction with the respective HAMP promoter fragment primer; 
amplification would occur only in the presence of a HAMP promoter amplicon inserted in the 
correct orientation.  Orientation of the insert was also confirmed using semi-automated 
bidirectional DNA sequencing analysis (see section 2.5). 
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Table 2.4 Primer and reaction specifications for colony PCR reaction 
Primer 
name 
Primer Sequences  
5’ – 3’ 
Tm  
(⁰C) 
TA1 TA2 PCR 
cycle 
MgCl2 
[mM] 
RV3 CTAGCAAAATAGGCTGTCCC  54 
55 N/A A 2 
PP3R TGAAGATCTCACCACACGTGCATAGGTT  61 
PP4R TGAAGATCTCCATCACGATGTCATTCTGC  60 
PP5R CTTTGCTCTGTCTCATTTCC  58 
Abbreviations: 5’, 5-prime; 3’, 3-prime; ⁰C, degrees Celsius; bp, base pair; F, Forward; mM, millimoles per 
liter; MgCl2, magnesium chloride; PCR, polymerase chain reaction; PP, promoter primer; R, Reverse; TA1, 
annealing temperature one; TA2, annealing temperature two; Tm, melting temperature. Tm = 2(nA + nT) + 4(nG + 
nC).   Note: the RV3 primer was used as the forward primer in conjunction with each of the reverse primers 
listed in the table. (For cycle A refer to section 2.2.2) 
 
2.9. Transformation and plasmid proliferation of pGL4 and β-Galactosidase 
(β-gal) plasmids 
 
Proliferation of the pGL4 (Fig 2.1 – 2.3) and β-Gal plasmids (Fig. 2.4) were performed by the 
transformation of EZ Competent cells (Qiagen) as per section 2.7.  A single colony was 
picked, and used to inoculate 150ml LB-Amp medium.  Inoculated cultures were then 
incubated overnight at 37⁰C, shaking at 180rpm.  Plasmid DNA extraction was then 
performed according to section 2.10. 
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2.10. Plasmid DNA extraction 
 
Plasmid DNA extraction was performed using the Qiagen Endofree Plasmid Maxi Kit.  
Cultures were allowed to proliferate to cell densities of approximately 3-4 x 109 cells per ml 
culture medium, then subsequently harvested by centrifugation at 6000 x gravity for 15 
minutes at 4⁰C.  Plasmid extraction was then executed according to the manufacturer’s 
instructions (Qiagen Plasmid Maxi Protocol).  The plasmid concentration obtained ranged 
between 1.8µg/μl and 3.0µg/μl. 
 
Fig 2.3 Schematic representation of the 
pGL4.73[hRluc2/SV40] vector (Promega) 
 
Fig 2.4 Schematic representation of the pSV-β-
Galactosidase control vector. (Promega) 
 
Fig 2.1 Schematic representation of the 
pGL4.10[luc2] promoterless vector (Promega) 
Fig 2.2 Schematic representation of the 
pGL4.23[luc2/minP] minimal promoter-containing 
vector. (Promega) 
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2.11. Transfection 
 
2.11.1. Cell preparation 
   
A HepG2 (ATCC®) liver cell line was used to investigate the effect of the identified HAMP 
promoter variants had on gene expression.  Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma) supplemented with 10% Foetal Bovine Serum (FBS) 
(v/v) (Sigma), 2mM L-Glutamine (Sigma) and 100U/ml Penicillin and Streptomycin (Sigma), 
incubated at 37ºC with an atmosphere of 5% CO2; 95% air.  HepG2 cells were washed using 
5ml DMEM medium prior to use, scraped from the flask and subsequently centrifuged at 
800rpm for 5 minutes at room temperature (Spectrafuge 24D, Labnet International).  The 
supernatant was discarded, and cells resuspended in 5ml fully supplemented DMEM 
medium.  This was then added to a flask containing a 10ml volume of fully supplemented 
DMEM medium and incubated under the atmospheric conditions as described above. 
Prior to transfection the cells were transferred to a six-well plate.  Fresh medium was added 
to the cells and subsequently evenly dispersed amongst the wells of a six-well plate.  Plates 
were incubated for a period of 24 hours to allow for confluence. 
 
2.11.2. Construct addition 
 
GeneJuice (Novogen; Merck) was used as a transfection reagent to facilitate the uptake of the 
construct by the HepG2 cell line.  GeneJuice was applied in a 1:1 µg DNA to µl GeneJuice 
ratio for effective transfection; and 50μl of fully supplemented DMEM medium was used for 
every 1μl of GeneJuice used during the transfection procedure.  For each transfection 200ng 
construct DNA and 100ng co-transfectant were used (β-Gal in the case of the promoterless 
constructs and pGL4.73 in the case of minimal promoter-containing constructs).  Each 
experiment comprised of triplicate runs (3 wells containing the same variant containing 
construct) and each experiment was performed three times. 
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2.11.3. Exogenous stimuli addition 
 
Twenty-four hours after the transfection procedure, exogeonous stimuli were added to the 
construct containing cultures.  Each construct was subjected to treatment with Ferric 
Ammonium Citrate (FAC) (C6H11FeNO7) (Fluka) to a final volume of 200µg/ml per well.  
Constructs were also subjected to treatment with human recombinant Interferon-γ (INF-γ) 
(Sigma) to a final concentration of 10ng/ml per well and lipopolysaccharides (LPS) (Sigma) 
to a final concentration of 10ng/ml per well. 
 
2.11.4. Luciferase assay 
 
The luciferase assay was used for the promoterless construct containing cultures.  Following 
induction, cells were harvested, lysed and assayed using a luciferase assay kit (Sigma).  
Medium was removed from the wells and each well washed three times with 1 x PBS 
solution (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4).  A volume of 
350ml cell culture lysis reagent (Sigma) (Sigma reagent constituents not available) was added 
to each well and plates incubated at room temperature for a period of 15 minutes.  The cells 
were subsequently scraped off the bottom of each well using a glass scraper and the contents 
of each well transferred to an appropriate 1.5ml Eppendorff tube for centrifugation at 16 000 
x g 1 minute at 4ºC.  The supernatants were removed and transferred to a new Eppendorff 
tube for storage at -80ºC.  The luciferase substrate and cell lysate containing luciferase were 
allowed to equilibrate to room temperature before use. Lysate (20µl per well) was pippetted 
into a 96-well microtiter plate and the plate transferred to a luminometer (Veritas™ 
Microplate Luminometer) for automated luciferase readings. An amount of 50μl luciferase 
substrate was automatically added to the appropriate wells and the relative light units (RLU) 
measured using the Veritas v2.0.4401 coupled software program (2sec delay, 8sec integration 
time). 
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2.11.5. Beta-Glo assay 
 
Beta-Glo assays were used for normalisation of the luciferase values obtained from the 
promoterless construct containing cultures, using a Beta-Glo Assay kit (Promega).  Briefly, 
the contents of the Beta-Glo Assay substrate and Beta-Glo Assay buffer bottles were 
combined and gently mixed.  A volume of 100μl of the cell lysate solution described in 
section 2.11.4 was added to the appropriate wells of a 96-well microtiter plate and 
subsequently 100μl of the combined Beta-Glo solutions added to each filled well.  A 30 
minute incubation period at room temperature was allowed giving the signal time to stabilise 
after which the signal was measured using a luminometer. 
The relative light units of the luciferase assay were normalised to the β-galactosidase 
readings obtained for each construct within an experiment.  This reading was subsequently 
normalised to the relevant wild-type sequencing containing construct used.  This allowed for 
a luciferase reading normalised to a co-construct, relative to the a WT. 
 
2.11.6. Dual-luciferase reporter assay 
 
Dual luciferase assays were performed using the Dual-Luciferase Reporter Assay Kit 
(Promega).  Medium was removed from each well of the six-well plate, and each well 
subsequently washed three times with 1 x PBS solution.  Active lysis of the cells was 
achieved by applying 300µl of 1 x Passive Lysis Buffer (PLB) (Promega) to each well and 
then immediately scraped using a sterile glass scraper.  The lysate was subsequently 
transferred to 1.5ml Eppendorff tube and frozen at -20ºC.  Following 1 – 2 freeze-thaw 
cycles, active cell lysis was completed. 
Cell lysates (20µl per well) were transferred to a 96-well microplate.  The plate was then 
transferred to a luminometer (Veritas™ Microplate Luminometer) for automated luciferase 
readings (Veritas v2.0.4401 software program).  The luminometer was programmed to add 
50µl of Luciferase Assay Reagent II (LARII) (kit supplied lyophilized Luciferase Assay 
Substrate in 10ml kit supplied Luciferase Assay Buffer II) (Promega) to each cell lysate with 
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a 2 second delay and 8 second reading time.  Luminometer, injector 2, was then utilised to 
add 50µl Stop & Glo® Substrate (1 x dilution of kit supplied Stop & Glo® Substrate using kit 
supplied Stop & Glo® Buffer) (Promega) to obtain renilla luciferase readings, present due to 
co-transfection with the pGL4.73 construct. 
 
2.12. Statistical analysis 
 
Allele and genotype frequencies were estimated and statistical differences between patient 
and control groups were tested for significance by the Fisher exact test and/or chi-squared 
(χ2) analysis.  The Hardy-Weinberg equilibrium (HWE) was performed to test equilibrium 
for the genetic traits investigated.  Box plots were used to identify outliers in the iron 
parameter data of patients and controls.  The F-test for variance was used to assess the type of 
t-test to be used and subsequently the student’s t-test for equal or unequal variances was 
carried out to determine statistically significant associations between patients and controls, 
males and females and within male and female cohorts, accordingly.  All tissue culture 
experiments were repeated three times with triplicate runs of each construct within each 
experiment.    The statistical analysis software R was used to investigate potential differences 
between constructs, separately for untreated as well as in the presence of exogenous stimuli.  
The dependent variable throughout was the log-ratio of luciferase to Beta-Glo/Renilla.  For 
each stimulus, a hierarchy of linear mixed-effects models was fitted (Pinheiro & Bates, 
2000), with the most appropriate model used to test for significant differences between 
constructs. This allowed various forms of heterogeneity to be modeled; runs were entered as 
random effects. Graphs of the multiplicative effects of the various constructs, in the original 
units, were produced in each case, together with 95% confidence intervals. Each run was 
investigated separately if there were significant inconsistencies between runs. Probability (P) 
values smaller than 0.05 were regarded as statistically significant. 
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CHARACTERIZATION OF THE PROMOTER REGION OF THE HAMP 
GENE IN OESOPHAGEAL CANCER 
 
ABSTRACT 
The hepcidin antimicrobial peptide gene (HAMP) encodes for a 25 amino acid protein, which 
has been found to be primarily expressed in liver tissue and is crucial to the regulation of 
bodily iron status.  Defects occurring in the promoter region of the HAMP gene may 
contribute to the dysregulation of the gene, resulting in an iron overload status.  Iron overload 
is a previously described risk factor in the development of various cancers, including 
oesophageal cancer (OC).   
The aim of this study was to investigate the promoter region of the HAMP gene in the Black 
South African population.  The HAMP promoter region of Black South African OC patients 
and a population-matched control group were subjected to mutation screening using 
polymerase chain reaction (PCR) amplification methods and heteroduplex single-stranded 
conformational polymorphism (HEX-SSCP) analysis. One previously described (-582A/G) 
and two novel (-188C/T and -429G/T) variants were identified in the 5’UTR region of this 
gene.  All variants were confirmed by bi-diectional semi-automated sequencing analysis.   
The novel variant located at position -429, relative to the transcriptional start site,  was found 
to occur at a high frequency within the patient cohort and was absent from the control group.  
The variant was found to disrupt a recently identified p53 response element; linking it 
directly to the cancer progression phenotype.  The use of this variant in the development of 
risk assessment and/or diagnostic test development, as well as cancer drug therapies, warrants 
further consideration.  Bioinformatic analysis of the -188C/T variant did not reveal it to 
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create or abolish any known transcription factor binding sites, where as the presence of the -
582A/G variant resulted in the disruption of a USF binding site. 
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INTRODUCTION 
Oesophageal cancer (OC) is the sixth leading cause of cancer related deaths in the world 
(Pisani et al., 1999), with the majority of OC classified as squamous-cell carcinoma (SCC) 
and adenocarcinoma (ADC).  The precise mechanisms of disease pathogenesis remain 
unclear. However, several factors have previously been associated with OC development, 
including irritation of the oesophageal tissues by oxidative damage, which may result from a 
variety of factors such as smoking and gastroesophageal reflux. This, in turn, can lead to 
inflammation of the oesophageal tissues and contribute to the carcinogenic process (Terry et 
al., 2000).  
The amount of dietary iron taken up by the body is tightly regulated as the body does not 
possess an active mechanism for iron excretion. Free radicals produced as a result of iron 
partaking in the Fenton Reaction have been shown to be damaging, therefore illustrating the 
vital role iron plays in facilitating cellular proliferation. Iron containing enzymes are 
responsible for the catalization of numerous metabolic reactions crucial to the efficient and 
effective progression of DNA synthesis and energy provision.  It is thus apparent that iron is 
vital for cellular proliferation and its availability therefore directly correlates to cancer cell 
development (Larrick and Cresswell, 1979; Chitambar et al., 1983). Cancerous tissues have 
been shown to absorb increased amounts of iron to sustain the rapid levels of their 
proliferation (Chan et al., 1987). The use of iron chelators, such as desferrioxamine, have 
also been used to inhibit the growth of aggressive tumours, highlighting the dependence of 
the tumour tissues on this trace element (Kwok and Richardson, 2002).  
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The hepcidin protein, encoded by the hepcidin antimicrobial peptide gene (HAMP), has been 
shown to be crucial for the regulation of iron metabolism. The protein is involved in the 
inhibition of the intestinal absorption of iron, induction of iron sequestration by macrophages 
and the blockage of iron transport across the placental barrier (Atanasiu et al., 2006). The 
HAMP gene is up-regulated in response to high levels of bodily iron and inflammation, 
resulting in increased production of the hepcidin protein, therefore preventing any further 
assimilation of iron at the intestinal lumen.  The hepcidin protein functions by binding to the 
membrane-bound protein, ferroportin (FPN), resulting in its internalisation and subsequent 
degradation.  With FPN being the only known mammalian iron exporter, iron is unable to be 
transported from the intestinal enterocytes and subsequently to the plasma.   
Recently, a p53 response element (p53RE) has been identified in the promoter region of the 
HAMP gene (Weizer-Stern et al., 2007). By means of deletion constructs, this response 
element has been identified to span positions -435 to -413 relative to the transcription start 
site.  It has been illustrated that the binding of the p53 tumour suppressor protein to the 
p53RE site results in the increased transcriptional activity of the HAMP gene. This results in 
reduced iron export amongst FPN expressing tissues and at the intestinal lumen.  The 
resulting iron deprivation experienced by cancer cell lines could result in cell cycle arrest or 
apoptosis, highlighting an alternative pathway for the tumour suppressor protein, p53, 
involved in cancer prevention and/or treatment (Weizer-Stern et al., 2007). 
In this study, we investigated the possible involvement of HAMP promoter variants in OC 
development by mutation analysis of the promoter region of the gene in a Black South 
African cohort.  
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MATERIALS AND METHODS 
Study cohort 
The study cohort consisted of 48 unrelated OC patients from the Black Xhosa-speaking 
population of South Africa, presenting with SCC of the oesophagus and displaying symptoms 
such as severe weight loss and dysphasia.  A barium swallow followed by a tissue biopsy was 
implemented to confirm the presence of a SCC phenotype on a histological basis.  Blood 
samples were obtained from the study patient cohort and from 51 healthy, unrelated 
population-matched individuals, the control cohort.  Control individuals were subjected to 
early OC screening by brush border biopsy. In this study “Black” refers to South Africans of 
central African descent.  
Methods 
See chapter 2 for detailed experimental procedures.  For simplicity, the luciferase constructs 
are numbered as shown in Table 3.1 for the rest of this section. 
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RESULTS AND DISCUSSION 
 
Mutation analysis, by means of HEX-SSCP, followed by bi-directional sequencing analysis, 
demonstrated the presence of three variants in the -1202 bp HAMP gene promoter fragment 
investigated.  These included one known (-582A/G: rs10421768) and two novel (-188C/T 
and -429G/T) variants.  The allele and genotype frequencies of these variants in the Black 
South African population are shown in Table 3.1.  A statistically significant association was 
observed for the -429G/T variant when comparing the patient (10 of 41) and population-
matched control (0 of 48) groups.  This variant was only observed in the heterozygous state. 
 
Table 3.1:  Allele and genotype frequencies of HAMP variants identified in the Black South African population 
  Allele Frequencies* Gentoype Frequencies   
Variant Patients Controls Genotype Patients Controls P 
-188 C/T 0.1 0.08 CC 0.82  ( 37) 0.84 (51) 0.870 
(this study) (n = 45)  CT 0.16   (7) 0.16 (10)  
   TT 0.02   (1) 0.00  (0)  
          
-429 G/T 0.12 0.00 GG 0.75 (31) 1.00 (48) 0.0002 
(this study) (n = 41)  GT 0.25 (10) 0.00  (0)  
   TT 0.00   (0) 0.00  (0)  
          
-582 A/G 0.09 0.08 AA 0.83 (34) 0.84 (72) 0.811 
(rs10421768) (n = 41)  AG 0.15  (6) 0.16 (14)  
      GG 0.02  (1) 0.00  (0)   
*Allele frequency representative of the polymorphic allele only; actual numbers are shown in parenthesis 
 
 
Chapter 3: Results 
51 
 
Iron parameters were obtained for all the patients and controls in this study. To further assess 
the effect of iron on disease expression, we performed statistical analyses on the iron 
parameters obtained.  The analyses were performed for patients and controls, in combination 
and separately for males and females.  This was performed because of the difference in 
“normal” parameters between males and females.  The data was further analyzed by grouping 
individuals with and without the presence of the variants and then analyzing iron parameters 
based on these groupings.  These groups included individuals with and without the identified 
variants within the patient group; as well as the variant presence and absence considering 
both patients and control individuals.  
Males and Females 
When comparing the female patient and female control groups,  the serum-iron, transferrin, 
ferritin and C-reactive protein levels (CRP) were found to be statistically significant (Table 
3.3).  Mean serum-iron and mean transferrin levels were found to be higher in the control 
females relative to the female patient group, whereas the mean ferritin and CRP levels were 
higher in the female patient groups relative to the female control group (Addendum A: Table 
6.2).  This corresponds to a higher level of iron being stored as ferritin in OC patients, as well 
as a higher level of inflammation as indicated by the increased levels of CRP protein 
(Kalantar-Zadeh et al., 2004).  The amount of transferrin present is dependent on the amount 
of serum-iron and therefore low serum-iron levels are paired to low transferrin levels.  The 
high level of iron stored as ferritin occurring amongst OC patients correlates with the reduced 
serum levels of iron available.  Male patients exhibit the same pattern of statistical 
significance as the females despite variating normality in iron parameters between sexes. 
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Table 3.2: Iron parameter statistics for female and male groups individually 
Description t-Test P-value Measured levels relative to controls 
Females 
serum iron 2.83712E-08 Lower in patients 
transferrin 1.75763E-27 Lower in patients 
%transferrin saturation 0.085466439 Not significant 
ferritin 0.000282725 Higher in patients 
CRP 0.000354578 Higher in patients 
Males 
serum iron 2.83712E-08 Lower in patients 
transferrin 5.04404E-07 Lower in patients 
%transferrin saturation 0.376404575 Not significant 
ferritin 2.08292E-05 Higher in patients 
CRP 1.53923E-06 Higher in patients 
 
Variant Influence on iron parameters 
Analyses were performed by grouping patients and controls with the variant (irrespective of 
homozygous or heterozygous state) vs. patients and controls without the variant.   
When ignoring OC presence, and grouping the patient and control groups into one, we 
considering focused on the presence and absence of variants for iron parameters (Table 3.3). 
No statistically significant associations were found considering the presence or absence of the  
-188C/T and -582A/G variants, however statistical significance was identified for serum-iron, 
transferrin, ferritin and CRP levels in the presence of the -429G/T variant.  Mean serum-iron 
and transferrin levels were elevated in the absence of the variant whereas mean ferritin and 
CRP levels were elevated in individuals heterozygous for -429G/T (Table 6.2).  Elevated 
ferritin levels are coupled to increased iron-bodily iron status (Kalantar-Zadeh et al., 2004) 
suggesting that the presence of the -429G/T variant results in under expression of the HAMP 
gene, since this would lead to an increase dietary iron assimilation.  
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Considering only the patient group, variant presence appeared to have a statistically 
significant association with transferrin levels and only in the case of the -188C/T and  
-429G/T variants (Table 3.4) Borderline significance was visualized for transferrin levels for 
the -582A/G variant (indicated in blue) (Table 3.4).  Mean values for transferrin were higher 
in patients without a heterozygous or homozygous version of the variant (including both the 
heterozygous and homozygous variants), which can be explained by a lower level of free 
transferrin available in the presence of the variant should the presence of the variant result in 
under-expression of the HAMP gene.  Reduced levels of the transferrin protein in the patient 
presenting with a variant, relative to patients without a variant suggests an interaction of the 
HAMP gene product with the Transferrin (TF) gene.  Further investigation is required to 
ascertain whether this is occurring, and this is warranted by statistics indicating that the 
presence of one of the identified variants in the HAMP promoter region results in a 
significant/ marginally significant reduction in transferrin levels in patients without the 
variant.   
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Description t-Test P-value In Patients 
 
Description t-Test P-value Variant Presence 
-188C/T Presence vs. -188C/T Absence 
 
-188C/T Presence vs. -188C/T Absence in Patients 
serum iron 0.33174998  
 
serum iron 0.386134878  
transferrin 0.351071062  
 
transferrin 0.031668925 lower 
%transferrin 
saturation 
0.237498835  
 
%transferrin 
saturation 
0.426561774 
 
ferritin 0.427797616  
 
ferritin 0.289366507  
CRP 0.218144757  
 
CRP 0.179977693  
-429G/T Presence vs. -429G/T Absence 
 
-429G/T Presence vs. -429G/T Absence in Patients 
serum iron 0.001002562 lower 
 
serum iron 0.077178176  
transferrin 4.33521E-09 lower 
 
transferrin 0.03485538 lower 
%transferrin 
saturation 
0.244405236  
 
%transferrin 
saturation 
0.459804835 
 
ferritin 0.043101444 higher 
 
ferritin 0.198577288  
CRP 0.02123364 higher 
 
CRP 0.469491084  
-582A/G Presence vs. -582A/G Absence 
 
-582A/G Presence vs. -582A/G Absence in Patients 
serum iron 0.239810997  
 
serum iron 0.213079178  
transferrin 0.382999266  
 
transferrin 0.057160041  
%transferrin 
saturation 
0.11662121  
 
%transferrin 
saturation 
0.357047402 
 
ferritin 0.45994801  
 
ferritin 0.4048286  
CRP 0.38771611  
 
CRP 0.217360868  
 
Functional analyses were performed on the three variants identified: These variants were 
tested in the absence and presence of exogenous stimuli, including FAC, INF-γ and LPS, 
respectively. 
The introduction of FAC mimics the occurrence of high intracellular iron levels.  INF-γ, a 
cytokine involved in innate and adaptive immunity against viral and intracellular bacterial 
infections and tumour control, should increase hepcidin production to facilitate the 
sequestering of iron by activated macrophage cells (Hayward et al., 2000).  LPS are large 
molecules found in the outer membranes of gram-negative bacteria.  They act as endotoxins 
eliciting a strong immune response upon detection by the body.  An increase in hepcidin 
Table 3.3: Iron parameter statistics representing variant 
presence or absence in the patients and controls. 
 
Table 3.4: Iron parameter statistics representing variant 
presence or absence in patients. 
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production would be advantageous in this situation reducing the amount of iron available to 
invading pathogens (Ulevitch and Tobias, 1999). 
The -188C/T variant 
The basal expression profile obtained for the -188T variant indicated a significant (P = 
0.0019) reduction in the amount of expression occurring relative to the -188C construct (Fig 
3.1).  When analysing the expression profiles for the various treatments, statistically 
significant under-expression was observed for both, INF-γ (P = 0.0293) and LPS (P = 
0.0493) addition relative to the WT, which has been subjected to the same relevant treatment.   
No statistically significant under-expression occurred relative to the WT construct upon FAC 
induction, but expression was observed to occur to a lesser degree compared to the WT 
sequence also FAC induced.  This suggests the presence of the -188C/T variant to 
significantly alter the regular expression profile of the HAMP gene under normal, and 
immune response conditions (Figures 3.1 – 3.4).  Data indicates the presence of the variant 
does not hamper the HAMP expression under high-iron conditions, even though under-
expression is observed relative to the WT in untreated experiments.  It is important to 
consider that the presence of the minimal promoter, designed to bring about construct 
expression, may be overshadowing the presence of a single variant within the promoter 
region being investigated.  The section of the HAMP gene included for minimal promoter 
investigation may not be able to function independently of its larger surrounding sequence 
region, and therefore the results obtained may be minimal-promoter driven.  Whole-promoter 
constructs containing the -188C/T variant need be investigated to confirm the results obtained 
using minimal-promoter containing constructs. 
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No whole-promoter constructs were prepared for the -188C/T variants as no individual 
presented with only the -188C/T variant for the -1202bp region under investigation.  Sit-
directed mutagenesis may be employed to allow for whole-promoter construct preparation, 
but due to time and funding constraints this was not performed for this study.  Future 
investigation considering whole-promoter analysis, however, need be carried out. 
Fig 3.2 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-188C/T promoter fragment, FAC treatment.  Data 
represent means of at least three independent 
experiments (+/- SEM). 
Fig 3.1 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-188C/T promoter fragment.  Data represent means 
of at least three independent experiments (+/- SEM) 
and statistically significant P values are represented 
by *.   P values less than 0.002 are considered to be 
statistically significant.     
* 
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The introduction of exogenous stimuli, showed under expression in the presence of the -188T 
variant relative to the WT, for untreated and all treatments.  Statistically significant 
associations were demonstrated for run1 and run3 of untreated, INF-γ and LPS addition.  
Bioinformatic analysis did not reveal the creation or abolishment of a known transcription 
factor binding sites for the variant containing region; however the presence of the variant 
notably hampers transcriptional regulation by resulting in reduced expression of the HAMP 
gene.  It can therefore be hypothesized that variant presence permits lower levels of hepcidin 
expression possibly allowing for a higher level of iron influx. 
 
* 
Fig 3.3 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-188C/T promoter fragments, INF-γ treatment.  
Data represent means of at least three independent 
experiments (+/- SEM) and statistically significant 
P values are represented by *.   P values less than 
0.05 are considered to be statistically significant.    
* 
Fig 3.4 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-188C/T promoter fragments, LPS treatment.  Data 
represent means of at least three independent 
experiments (+/- SEM) and statistically significant 
P values are represented by *.   P values less or 
equal to than 0.05 are considered to be statistically 
significant.    
* 
* 
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Fig 3.5 Electropherograms indicating (A) the wild-type 
sequence (B) the -429G/T variant in heterozygous state.  The 
arrows indicate the point of variation. 
 
A 
B 
The -429G/T variant 
A novel variant, a G to T transition at nucleotide position -429, demonstrated statistically 
significant differences between the patient (10 of 41) and control (0 of 51) cohort and was 
only identified in a heterozygous state. Although this variant has not been detected in our 
control population, it has been identified at a frequency of 1% (1 of 100) in a previous study 
performed in our laboratory in individuals of a South African Mixed Ancestry population 
(Panton et al., 2008). The electropherogram indicating the -429G/T variant can be visualized 
in Figure 3.5. 
 
The -429G/T variant is localised within an area previously identified as a response element 
for the p53 tumour response protein (p53RE) (Weizer-Stern et al., 2007).  The response 
element was found to span the region -435 to -413, relative to the transcription start site. 
Applications using deletion construct preparations and electromobility shift assays confirmed 
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binding of the p53 protein to this region.  Weizer-Stern et al. (2007) also showed that the 
induction of single nucleotide polymorphisms within this region resulted in reduced binding 
affinity of the p53 protein.  The presence of the -429G/T variant could therefore result in 
reduced p53 binding, or may inhibit binding completely.  
The identification of a p53RE in the promoter region of the HAMP gene suggests the 
potential involvement of HAMP in cancer phenotype presentation.  It was shown that binding 
of the p53 tumour suppressor to the p53RE region results in up-regulation of HAMP gene 
expression and increased production of the hepcidin protein.  The presence of increased 
hepcidin protein subsequently allows for decreased absorption of iron, cutting off a vital 
resource required for the proliferation of cancer cells.  Iron parameter statistics confirm this 
hypothesis indicating a large increase in the amount of ferritin in patients presenting with the 
-429G/T mutation; and increased CRP levels, a measure of inflammation in individuals 
heterozygous for the variant (Table 3.3).   
The TP53 gene was investigated for this study.  A subset of 20 patients (WT and 
heterozygous for the -429G/T variant) and 20 controls were selected for, and subjected to 
mutation analysis for TP53.  Screening of the TP53 gene revealed no detectable variation in 
patients or controls.  Tumour tissue samples (subset of 20 patients) were sent to an 
appropriate laboratory authority for p53 immunohistochemical and iron staining.  No aberrant 
results were obtained but this may be due to the age of the tumour samples used and the fact 
that they were frozen beforehand.  No conclusive results could therefore be deduced from this 
data. 
Luciferase activity from the -429T whole-promoter construct showed a significant (P = 
0.0329) reduction when compared to that of the -429G whole-promoter construct 
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demonstrating that the presence of the variant within the recently identified p53RE decreased 
transcriptional activity relative to the WT (Figure 3.6).  Induction with FAC should result in 
an upregulation of the HAMP gene in response to a higher level of iron present, and 
subsequently a reduction in the amount of iron absorption required.  The introduction of FAC 
still allowed for statistically significantly reduced levels of expression in the presence of the  
-429G/T variant relative to Luc9 (P < 0.0001) (Figure 3.7).   
In the case of INF-γ addition, the same trend in expression was observed as in the cases of 
untreated and FAC addition; however there was statistically significant variation between the 
three experimental runs carried out.  This inconsistency could account for the lack of 
significance observed between -429G and -429T constructs, and therefore individual runs 
were considered (Figures 3.8 – 3.9).  Run 1 exuded aberrant results to what is theoretically 
expected (we expect an under-expression in the presence of the variant); however runs two 
and three showed the same trend of under-expression in the presence of the variant, although 
only run 2 showing statistical significance (P = 0.0006).  Repeat experiments for this stimulus 
are warranted to confirm the results obtained.  INF-γ, a cytokine involved in innate and 
adaptive immunity against viral and intracellular bacterial infections and tumour control, 
increases hepcidin production to facilitate the sequestering of iron by activated macrophage 
cells.  Under-regulation relative to the -429G construct suggests more iron available to 
invading pathogens during infection in the presence of the -429T variant.  
LPS are large molecules found in the outer membranes of gram-negative bacteria.  They act 
as endotoxins eliciting a strong immune response upon detection by the body.  An increase in 
hepcidin production would be advantageous in this situation reducing the amount of iron 
available to invading pathogens.  The addition of LPS resulted in a significant increase (P = 
0.0001) in the amount of expression occurring relative to the -429G construct, surpassing that 
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of -429G levels (Figure 3.10).  This suggest the presence of the -429G/T variant, although 
detrimental to HAMP regulation, will allow for appropriate action under threat of bacterial 
infection.  Increased hepcidin expression in the presence of invading pathogens will result in 
a restriction in the amount of iron available to them for survival. 
When using minimal promoter constructs no significant differences were found comparing 
variant containing and wild-type sequence containing constructs (Figures 3.11 – 3.14).  It can 
be hypothesised that the presence of a strong minimal promoter overshadows the effect the 
presence a single variant may have on gene expression.  The theory of the particular region 
being incorporated into the vector not being able to function adequately without its larger 
respective adjacent 5’UTR regions to facilitate its function, must also be considered.  The 
region incorporated may be lacking the adjacent sequences necessary to adequately regulate 
expression of the proceeding gene. 
 
 
 
 
 
 
* 
Fig 3.6 Luciferase assay results for promoterless pGL4 
vectors containing WT, -429G/T and -582A/G whole 
promoter inserts.  Data represent means of at least three 
independent experiments (+/- SEM) and statistically 
significant P values are represented by *.   P values less 
than 0.05 are considered to be statistically significant.   
* 
*  
* 
* 
 
Fig 3.7 Luciferase assay results for promoterless pGL4 
vectors containing WT, -429G/T and -582A/G whole 
promoter inserts, FAC treatment.  Data represent means of at 
least three independent experiments (+/- SEM) and 
statistically significant P values are represented by *.   P 
values less than 0.05 are considered to be statistically 
significant.   
* 
* 
* 
* 
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Fig 3.10 Luciferase assay results for promoterless pGL4 
vectors containing WT, -429G/T and -582A/G whole 
promoter inserts, INF-γ treatment (Run3).  Data represent 
means of at least three independent experiments (+/- SEM) 
(Fitted using ML instead of REML) 
Fig 3.8 Luciferase assay results for promoterless pGL4 
vectors containing WT, -429G/T and -582A/G whole 
promoter inserts, INF-γ treatment (Run1).  Data represent 
means of at least three independent experiments (+/- SEM) 
and statistically significant P values are represented by *.   P 
values less than 0.05 are considered to be statistically 
significant.  (Fitted using ML instead of REML) 
  
* 
 
* 
Fig 3.11 Luciferase assay results for promoterless pGL4 
vectors containing WT, -429G/T and -582A/G whole 
promoter inserts, LPS treatment.  Data represent means of at 
least three independent experiments (+/- SEM) and 
statistically significant P values are represented by *.   P 
values less than 0.005 are considered to be statistically 
significant.   
* 
 
* 
 
* 
* 
Fig 3.9 Luciferase assay results for promoterless pGL4 
vectors containing WT, -429G/T and -582A/G whole 
promoter inserts, INF-γ treatment (Run2).  Data represent 
means of at least three independent experiments (+/- SEM) 
and statistically significant P values are represented by *.   P 
values less than 0.005 are considered to be statistically 
significant.  (Fitted using ML instead of REML) 
* 
* 
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Fig 3.12 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-429G/T promoter fragments.  Data represent 
means of at least three independent experiments 
(+/- SEM). 
Fig 3.13 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-429G/T promoter fragments, FAC treatment.  Data 
represent means of at least three independent 
experiments (+/- SEM). 
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Fig 3.14 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-429G/T promoter fragments, INF-γ treatment.  
Data represent means of at least three independent 
experiments (+/- SEM). 
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Fig 3.15 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-429G/T promoter fragments, LPS treatment.  Data 
represent means of at least three independent 
experiments (+/- SEM). 
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The -582A/G variant 
Bioinformatic analysis of the -582A/G variant predicted that the presence of this variant may 
disrupt a vertebrate transcriptional binding site for the upstream stimulatory factor (USF) 
transcription factor (Heinemeyer et al., 1998). USF proteins are members of the basic-helix-
loop-helix family of transcription factors directly involved in the up-regulation of 
transcriptional activity.  They exhibit divergence in their N-terminal sequences; however,  
C-terminal sequences show high levels of conservation attesting to a high degree of necessity 
(Jiang et al., 2000).  Luciferase activity for the -582G plasmid construct showed a statistically 
significant (P = 0.0073) increase in the amount of expression occurring in the presence of the 
variant relative to the WT plasmid construct (Figure 3.6).  The addition of FAC resulted in 
decreased transcriptional activity; however, these values were still above that of the wild-type 
expression levels obtained (Figure 3.7).   
wwwIn the case of INF-γ addition there was the same general trend of over-expression 
relative to the WT sequence of -582A.  No statistically significant values were obtained, but 
this could be due to statistically significant deviation found between the three experimental 
runs performed for INF-γ.  Considering the runs individually (Figures 3.8 – 3.10), run 1 
exhibited an aberrant expression profile to what is expected, however runs 2 and 3 showed 
over – expression relative to the WT construct with run 2 at statistically significant levels (P 
= 0.0032).  Replicate runs for INF-γ addition are required to verify these findings.  LPS 
addition yielded no significant differences from the WT construct suggesting, as in the case -
429T, the presence of the -582A/G variant will allow for an appropriate HAMP expression 
profile under threat of bacterial infection (Fig 3.11). The presence of the -582A/G variant 
therefore appears to result in an upregulation in the basal expression of the HAMP gene, to 
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levels equal to those observed with WT sequence, suggesting that the presence of the variant 
will not alter the HAMP expression profile in response to bacterial infection. 
Minimal promoter results for the -582A/G variant relative to its wild-type sequence construct 
did not indicate any statistically significant deviations. This suggests, as in the case with the  
-429G/T minimal-promoter containing construct, that the presence of a strong minimal 
promoter overshadows the effect of a single variant on gene expression (Figures 3.16 – 3.19).  
The fragment containing the -582A/G variant may also not be able to function independently 
of a larger region of its adjacent sequence necessary for it to effectively regulate the 
expression of a proceeding gene.  Further studies investigating the importance of regions of 
the 5’UTR of the HAMP gene are required to access the necessity of particular ‘blocks’ for 
transcriptional regulation of the HAMP gene it precedes. 
  
Fig 3.16 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-582A/G promoter fragments.  Data represent 
means of at least three independent experiments 
(+/- SEM).  
Fig 3.17 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-582A/G promoter fragments, FAC treatment.  Data 
represent means of at least three independent 
experiments (+/- SEM).  
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Concluding remarks 
Iron parameter statistics indicate an overall higher level of ferritin storage in male individuals 
compared to female individuals.  This can be explained by females losing iron with each 
menstruation cycle resulting in a slower progression to the ferritin levels seen in males.  This 
coincides with statistics putting male individuals at an increased likelihood to develop OC.   
Iron parameter statistics also indicate elevated ferritin and CRP levels in individuals 
heterozygous for the -429G/T variant.  This correlates with the decreased transcriptional 
activity observed with luciferase constructs possessing the variant relative to wild-type 
constructs. Under expression of the HAMP gene would ultimately lead to elevated ferritin 
stores, due to the increased level of iron absorption that would result.  The disruption of the 
Fig 3.18 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-582A/G promoter fragments, INF-γ treatment.  
Data represent means of at least three independent 
experiments (+/- SEM).  
Fig 3.19 Luciferase assay results for minimal-
promoter pGL4 vectors containing WT and  
-582A/G promoter fragments, LPS treatment.  Data 
represent means of at least three independent 
experiments (+/- SEM).  
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p53RE site preventing upregulation of the gene and the involvement of this variant in cancer 
phenotype progression is noteworthy. 
The -582A/G and -429G/T variants were identified exclusively in the heterozygous state in 
the Black South African OC population screened.  Luciferase analyses of these variants 
indicate that the variants have opposing expression profiles.  Statistical analyses of these two 
variants, in relation to the WT construct, yielded statistically significant results (P = 0.001) 
(Figure 3.6) and therefore the investigation of the simultaneous presence of these variants 
within a single patient is warranted.   
Overall results suggest that mutations in the HAMP promoter may alter iron homeostasis, and 
in the case of the -188C/T and -429G/T variants could result in an iron burden which may 
prove to be advantageous to cancer phenotype presentation and/or progression.  The presence 
of the -429G/T mutation within a p53RE could also represent an alternative pathway whereby 
the p53 tumour suppressor protein is able to control/prevent tumour development. 
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4. Conclusion 
 
The study objectives consisted of the identification of novel and/or previously described 
variants in an OC patient cohort and subsequent functional analyses of these variants to 
identify the effect variants may have on gene expression.  It also involved the assessment of 
iron parameter statistics regarding patient and control cohorts in order to better assess the 
genotype-phenotype correlations observed between healthy and OC afflicted individuals, 
taking into account the presence and absence of the identified variants. 
In this study, in accordance with the first objective, three variants were identified in the 
promoter region of the HAMP gene, of which one was known (-582A/G) and two which were 
novel (-188C/T and -429G/T).  This was accomplished using PCR amplification of 1202bp of 
the 5’ UTR of the HAMP gene and subsequent HEX-SSCP analysis and semi-automated bi-
directional sequencing analyses.  The HEX-SSCP technique has a 70% sensitivity rating 
(Kotze et al., 1995) and it is therefore possible that other variants within the promoter region 
may not have been detected using this type of screening method.   
The three variants identified within the HAMP promoter region were functionally 
investigated by transfection into a HepG2 cell line of variant containing pGL4 minimal and 
promoterless vector constructs.   This was performed in both the absence and presence of 
exogenous stimuli, namely FAC, INF-γ and LPS.  Statistically significant effects were found 
with all three variants investigated, relative to their WT sequencing constructs included in 
functional investigations.  Considering the basal levels of expression observed in untreated 
expression runs, statistically significant effects in the presence of a variant, relative to the 
respective WT construct used.  A variant within the promoter region of the HAMP gene is 
therefore able to alter its expression, depending on its location.  Hepcidin plays an absolutely 
critical role in iron regulation, and therefore the disruption of the wild-type gene expression 
profile within tissues could result in an iron burden or iron starvation of cells.  Each of these 
could have severe consequences.  The presence of the -582 G/T variant, based on the 
luciferase results obtained, appears to result in an increase in the basal (i.e. un-induced) 
amount of hepcidin produced.  This would subsequently result in reduced iron influx, 
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contributing to an anemia phenotype, and iron sequestration by macrophages.  The presence 
of the -429 G/T and -188 C/T variants, based on the luciferase results, appear to result in 
reduced basal levels of HAMP expression.  The resulting reduced levels of hepcidin could 
result in a higher influx of iron in the intestinal lumen leading to an iron overload phenotype.  
Iron overload is associated with a variety of disorders including haemochromatosis.  
Mutation of the HAMP gene has previously been linked to a severe form of 
haemochromatosis, namely juvenile haemochromatosis.  The presence of high iron also 
facilitates the production of free radicals, increasing susceptibility to cancer.  It is also 
important to note that cancerous cell lines require large amounts of iron for propagation.  The 
hypothesis that a higher iron status may promote the creation of cancerous cells or facilitate 
increased propagation of already existing cancerous cells merits further investigation. 
 
The -429G/T variant was identified exclusively in the heterozygous state in the Black Xhosa-
speaking South African OC population screened, and the -582A/G variant as exclusively 
heterozygous with the exception of a single patient that was homozygous.  Luciferase 
analyses of promoter reporter constructs containing these variants indicate that the variants 
have opposing expression profiles.  Statistical analyses of these two variants yielded 
statistically significant results (Untreated: P = 0.001; FAC: P < 0.0001; INF-γ; run2, P < 
0.0001; LPS: P = 0.0002) considering the simultaneous effect of both variants in relation to 
WT constructs (Figures 3.6 – 3.11) and therefore the investigation of the simultaneous 
presence of these variants within a single patient is warranted.  The opposing expression 
profiles observed indicates the possibility of compensation occurring, considering the 
simultaneous presence of the -429G/T and -582A/G variant in a single patient.  The same 
theory can be assigned to the simultaneous presence of the -188C/T and -582A/G variants 
based on the expression profiles obtained.  Considering the simultaneous presence of the  
-188C/T and -429G/T variants, an additive effect may be observed resulting in sever iron 
overload in patients possessing these two variants.  The simultaneous presence of any of the 
three variants identified in this study occurring within a single individual was not identified 
within this study.  The merits of the additive or compensatory effect combinations of these 
variants may have on expression could prove useful to the further understanding of the 
transcriptional regulation of the HAMP gene and possibly be beneficial for future genetic 
application. 
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This study investigated the role of promoter dysregulation of the HAMP gene in OC 
development and/or progression.  Iron parameters were statistically correlated to provide 
further insight into OC presentation between patients and controls, males and females, and 
individuals presenting with and without variation in their HAMP promoter region.  The 
significant association identified with the -429G/T variant suggests its possible association 
with OC susceptibility.  This is further supported by its statistically significant frequency in 
the patient cohort, relative to the controls as well as statistically significant under-expression 
relative to WT sequence in culture. Genotype-phenotype correlations were therefore 
investigated and significant correlations were found between certain variants and iron 
parameter values observed. 
Limitations of this study and future prospects 
The study cohorts used were representative of a pilot study.  Expansion of the patient and 
control groups to ascertain whether the obtained frequencies remain constant in the Black 
Xhosa-speaking South African population may contribute to strengthening of the results 
obtained in this study.  Identification of raised frequencies upon cohort expansion would 
further strengthen the correlation of the identified variants to OC susceptibility.  Expanding 
the study population to include South African Caucasian and Mixed Ancestry individuals 
could provide valuable statistical information on the identified variants and contribute to the 
improvement of diagnostic and counseling services for the unique populations of this 
country.  
Considering the presence or absence of significant variance between runs, different statistical 
models were used to assess the effect that a particular variant has in relation to the respective 
WT.  This hampered our ability to combine data sets to ascertain the fold-expression 
increases or decreases of variants relative to each other, and whether the same level of 
increase or decrease in expression was occurring upon treatment addition as was visualized in 
untreated cases for each variant considered.  Replicate experiments aimed at reducing the 
level of variance observed are required. These will allow for the investigation of the 
aforementioned comparisons, and will provide valuable insight into the degree to which 
transcriptional up-regulation or down-regulation occurs in the presence a variant.  
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Further research including screening for novel and previously described variants in other 
genes involved in iron metabolism, including TF, TRF1 and TFR2 need be carried out to 
investigate the potential role these genes may have in OC development.  Genes which have 
already been subjected to mutation screening within our research group (HFE, CP and 
SCL40A1) may be correlated to assess the interaction of gene mutation in contributing to the 
cancer phenotype and progression, and iron status.  Investigation of the regulation of the 
HAMP gene will contribute to this investigation.   Iron metabolism is an intricate 
combination of pathways involving numerous genes and protein interactions.  The correlation 
of multiple genes involved in iron metabolism could provide necessary insight into the 
understanding of OC susceptibility and iron. 
In this study there were noteworthy differences between the mean ages of patient and control 
groups, with control individuals having mean age higher than that of the patient cohort.  This 
is not optimal considering iron loading in patients is age dependent in most cases.  
Investigation of the ages of individuals in the patient and control cohorts, however, indicated 
individuals of both groups, to be over the age of 50 years.  Mutations within the HAMP gene 
are associated with early onset iron disorders, lessening complications caused by the 
discrepancy between ages.  Individuals above the age of 50 should be showing iron loading 
symptoms to a certain degree.  This discrepancy, however, remains something to be 
considered in future studies. 
This study successfully identified novel and previously described variants in the promoter 
region of the HAMP gene in the Black Xhosa-speaking South African population.  Significant 
associations were observed considering variant presence in relation to WT sequence, 
implicating the variants identified in OC susceptibly.  In conjunction with further research 
this study may prove an important contribution to understanding the current association of 
iron dysregulation in the development and/or progression of OC. 
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Addendum A 
6.1. Mutation analysis, construct preparation and iron parameter statistics 
 
i. HAMP promoter 
 
Sequence chromatograms and 12% PAA HEX-SSCP gel depictions of the variants identified.  
 
 
 
 
 
 
 
 
 
 Fig 6.1 Electropherograms indicate (A) the -188 C/T 
variant in heterozygous state and (B) the wild-type 
sequencing pattern.  Arrows indicate the point of change. 
 
A 
B 
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ii. TP53 
 
Screening of the TP53 gene revealed no detectable variation in the screened regions (Table 
2.2).  Semi-automated bi-directional sequencing performed on select samples depicting HEX-
SSCP variation confirmed individuals to be wild-type for the particular sequences under 
investigation. 
 
 
Fig 6.2 Electropherograms indicate (A) the -429 G/T 
variant in heterozygous state and (B) the wild-type 
sequencing pattern.  Arrows indicate the point of change. 
 
A 
B 
Fig 6.3 Electropherograms indicate (A) the -582 A/G 
variant in heterozygous state and (B) the wild-type 
sequencing pattern.  Arrows indicate the point of 
change. 
 
A 
B 
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iii. Construct Preparation 
 
PCR amplification of the HAMP promoter region in question was carried out using the 
protocol outlined in section 2.6.  Successfully amplified PCR products were purified and 
subjected to digestion according to section 2.6.2.  Post digestion products were once again 
purified and subsequently subjected to ligation according to section 2.6.3.  Ligation success 
was tested enzymatically by digesting with a single enzyme, namely NheI.  The results of 
these digestions are shown in Figs 6.4 and 6.5.  Standard plasmid (without insert) is shown as 
the smaller band with successful digestions yielding bands higher up in the gel.  The increase 
in band size correlates directly with the size of the incorporated insert.  
  1 KB           pGl4.10      -429 G/T      -582 G/T        
Fig 6.4 Agarose gel depiction (1.5% w/v) 
of the test ligation digest using the NheI 
enzyme for promoterless containing 
constructs.  Annotations -429G/T and  
-582A/G refer to constructs containing the 
relevant variant containing inserts.  The 
pGL4.10 depiction represents digested 
plasmid with the absence of insert. The 
pGL4.10 lane represents a fragment of 
4242bp with the other lanes indicating 
band sizes approximately the relevant 
insert size larger. (-429G/T: 4554bp and  
-582A/G: 4568bp)  
 
           pGL4.23      -188 C/T    -429 G/T      -582 A/G 1 KB 
Fig 6.5 Agarose gel depiction (1.5% w/v) of the test 
ligation digest using the NheI enzyme for minimal 
promoter containing constructs.  Annotations  
-188C/T, -429G/T and -582A/G refer to constructs 
containing the relevant variant containing inserts.  The 
pGL4.23 depiction represents digested plasmid with the 
absence of insert. The pGL4.23 lane represents a fragment 
of 4283bp with the other lanes indicating band sizes the 
relevant insert size larger. (-188C/T: 4568bp, -429G/T: 
4595bp and -582A/G: 4609bp) 
1000bp 
1000bp 
4283bp 
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iv. Transformation and Insert Confirmation 
 
With ligation confirmed, transformation was performed according to the methodology 
outlined in section 2.9.  Colonies were visualized on all plates with no colonies observed on 
the negative control plates prepared for each transformation procedure carried out (Fig 6.6).  
The colonies visualized must, at the very least, contain the pGL4 constructs as they contain 
the gene conferring ampicillin resistance allowing only ampicillin resistant bacterial strains to 
grow.  This was confirmed by the absence of any colonies on the negative control plates and 
multitudes of colonies observed on the positive plates prepared. 
A B 
Fig 6.6 Successful transformation plating grown overnight at 
37ºC. The (A) -429 G/T, (B) -582 A/G, (C) WT plating 
indicates growth on LB-agar plates containing ampicillin as 
selective marker.  (D), the negative control shows no growth 
indicative on the absence of pGL4.10 vector bestowing 
antibiotic resistance. Similar results were obtained for minimal 
promoter transformations using pGL4.23 (not shown). 
 
 
D C 
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Colony PCR was performed on randomly selected colonies on individual plates and the 
products subjected to semi-automated DNA sequencing analysis to confirm the presence and 
orientation of the desired insert (Fig 6.7 and 6.8).  Colonies exhibiting positive results for the 
desired variants were then cultured and subjected to plasmid extraction according to section 
2.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 bp  -429     -582      -582      Wt 
Fig 6.8 Agarose gel depiction of colony PCR 
amplifications for promoterless constructs containing  
-429 G/T, -582 A/G and WT.  Amplifications were 
performed using RV3 and PP5R primers.  Successful 
results were achieved for all colonies picked. 
 
1 Kb    1        2        3         4         5        6       7       8       9        10     11      12     13      14      15  
Fig 6.7 Agarose gel depiction (1.5% w/v) of colony PCR amplification for minimal 
promoter constructs containing -188 C/T.  A WT for the PP5 fragment was also prepared 
and subjected to colony PCR although not depicted here. Amplifications were performed 
using RV3 and PP5R primers. 
250bp 
500bp 
1000bp 
100bp 
500bp 
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v. Iron parameter descriptive statistics for male and female patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Equal Variances
Female Patients Female Controls Male Patients Male Controls
Mean 6.581818182 11.355 Mean 7.376 12.9625
Variance 7.798701299 15.50934177 Variance 6.6144 10.9545
Observations 22 80 Observations 25 16
Hypothesized Mean Difference 0 Pooled Variance 8.283669231
df 47 Hypothesized Mean Difference 0
t Stat -6.445814285 df 39
P(T<=t) one-tail 2.83712E-08 t Stat -6.062705825
t Critical one-tail 1.677926722 P(T<=t) one-tail 2.83712E-08
P(T<=t) two-tail 5.67424E-08 t Critical one-tail 1.684875122
t Critical two-tail 2.01174048 P(T<=t) two-tail 4.23769E-07
t Critical two-tail 2.022690901
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances
Female Patients Female Controls Male Patients Male Controls
Mean 1.017142857 2.001168831 Mean 1.227041667 2.2195625
Variance 0.028740629 0.186921984 Variance 0.071725259 0.281061196
Observations 21 77 Observations 24 16
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 84 df 20
t Stat -15.97108168 t Stat -6.922806428
P(T<=t) one-tail 1.75763E-27 P(T<=t) one-tail 5.04404E-07
t Critical one-tail 1.66319668 t Critical one-tail 1.724718218
P(T<=t) two-tail 3.51526E-27 P(T<=t) two-tail 1.00881E-06
t Critical two-tail 1.988609629 t Critical two-tail 2.085963441
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances
Female Patients Female Controls Male Patients Male Controls
Mean 243.3605 76.655625 Mean 283.8484 95.357
Variance 32212.08475 1302.89985 Variance 33983.76081 1690.036712
Observations 20 80 Observations 25 10
Hypothesized Mean Difference 0 Hypothesized Mean Difference 0
df 19 df 29
t Stat 4.133035547 t Stat 4.821470861
P(T<=t) one-tail 0.000282725 P(T<=t) one-tail 2.08292E-05
t Critical one-tail 1.729132792 t Critical one-tail 1.699126996
P(T<=t) two-tail 0.000565449 P(T<=t) two-tail 4.16584E-05
t Critical two-tail 2.09302405 t Critical two-tail 2.045229611
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances
Ferritin Ferritin
CRP CRP
Serum-Iron Serum-Iron
Transferrin Transferrin
        
Female Patients Female Controls Male Patients Male Controls
Mean 24.82105263 4.032133333 Mean 18.06666667 1.941666667
Variance 490.0561988 16.60087377 Variance 133.6123333 4.873560606
Observations 19 75 Observations 21 12
Hypothesized Mean Differe 0 Hypothesized Mean Difference 0
df 18 df 22
t Stat 4.075962794 t Stat 6.197971702
P(T<=t) one-tail 0.000354578 P(T<=t) one-tail 1.53923E-06
t Critical one-tail 1.734063592 t Critical one-tail 1.717144335
P(T<=t) two-tail 0.000709155 P(T<=t) two-tail 3.07847E-06
t Critical two-tail 2.100922037 t Critical two-tail 2.073873058
Table 6.1 Two Sample t-Test for iron parameters considering male and female groups individually. 
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 t-Test: Two-Sample Assuming Equal Variances 
 
Serum-Iron CRP 
  429G/T WT 429G/T WT 
Mean 5.89 10.04868421 21.0875 9.96880597 
Variance 9.601 15.67693158 319.1955357 195.294044 
Observations 10 76 8 67 
Pooled Variance 15.02593891 
 
207.175009 
 Hypothesized Mean Difference 0 
 
0 
 df 84 
 
73 
 t Stat -3.189280405 
 
2.065079898 
 P(T<=t) one-tail 0.001002562 
 
0.02123364 
 t Critical one-tail 1.66319668 
 
1.665996224 
 P(T<=t) two-tail 0.002005123 
 
0.04246728 
 t Critical two-tail 1.988609629 
 
1.992997097 
 
 
t-Test: Two-Sample Assuming Unequal Variances 
 
Ferritin Transferrin 
  429G/T WT 429G/T WT 
Mean 309.5066667 139.1478873 0.988777778 1.777554054 
Variance 66604.65378 13198.69463 0.044436694 0.377040881 
Observations 9 71 9 74 
Hypothesized Mean Difference 0 
 
0 
 df 8 
 
30 
 t Stat 1.955898189 
 
-7.874953728 
 P(T<=t) one-tail 0.043101444 
 
4.33521E-09 
 t Critical one-tail 1.859548033 
 
1.697260851 
 P(T<=t) two-tail 0.086202887 
 
8.67042E-09 
 t Critical two-tail 2.306004133   2.042272449   
Table 6.2: Descriptive statistics considering the presence and absence of the -429G/T variant among the 
combined patient and control groups 
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Addendum B 
6.2. Conference outputs 
 
Paper presented as an oral presentation: 
SASHG Conference, Spier Stellenbosch (5 – 8 April 2009) Abstract Submission 
Characterization of the promoter region of the HAMP gene implicated in iron 
metabolism and its possible association with Oesophageal cancer in the Black South 
African population 
*N.W McGregor, *M. G Zaahl 
*Department of Genetics, University of Stellenbosch, JC Smuts Building, De Beer Street, Stellenbosch, 7600 
ABSTRACT 
OBJECTIVES:  The HAMP gene codes for the 25 amino acid, hepcidin protein, crucial to the 
regulation of the bodily iron status.  Defects occurring within the promoter region of this gene 
may contribute to its dysregulation, subsequently resulting in an iron overload status.  Iron 
overload status is a previously described risk factor in the development of numerous cancers, 
oesophageal cancer (OC) included, and therefore the dysregulation of the HAMP gene may 
be involved in cancer phenotype exhibition. 
METHODS: Approximately 1500 bp of the 5’UTR of the HAMP gene was subjected to 
mutational analysis in order to determine to effect of promoter variants on gene expression.  
Fifty Black, Xhosa-speaking South African individuals were screened against a cohort of 50 
population matched controls. 
RESULTS:  Four variants were identified within the screened promoter region: -153 C/T,  
-188 C/T, -429 G/T and -582 A/G; with the -429 G/T variant being of particular interest.  The 
-429 G/T variant is found to disrupt a previously identified p53 response element required for 
the up-regulation of HAMP gene expression.  
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CONCLUSIONS:  Variants occurring within the promoter region of the HAMP gene are 
indeed able to alter gene expression, provided they occur at points crucial to the 
transcriptional regulation of the gene.  Dysregulation of the HAMP gene results in an 
increased uptake of dietary iron, which in turn could feed the proliferation of carcinogenic 
cells lines. 
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Paper presented as an oral presentation: 
Bio-Iron: Porto, Portugal  (7 – 11th June, 2009) Abstract Submission 
CHARACTERIZATION OF THE PROMOTER REGION OF THE HAMP GENE IN THE BLACK 
SOUTH AFRICAN POPULATION AND ITS POSSIBLE ASSOCIATION WITH OESOPHAGEAL 
CANCER 
1N.W McGregor, 2A Louw, 1L Warnich, 1M. G Zaahl 
Departments of 1Genetics and 2Biochemistry, University of Stellenbosch, JC Smuts Building, De Beer Street, 
Stellenbosch, 7600 
ABSTRACT 
OBJECTIVES:  The HAMP gene; encoding for the 25 amino acid hepcidin protein, is 
paramount in the regulation of the bodily iron status.  Mutations disrupting the regular 
expression of this gene may therefore result in an irregular bodily iron standing, i.e. iron 
overload.  An iron overload status is a previously described risk factor in the development of 
numerous cancers, oesophageal cancer (OC) included, and therefore the dysregulation of the 
HAMP gene may be involved in cancer phenotype exhibition. 
METHODS: Mutational analysis of approximately 1500 bp of the 5’UTR of the HAMP gene 
was performed to determine the effect of promoter variants identified on gene expression. 
Initially, fifty Black, Xhosa-speaking South African individuals were screened against a 
cohort of 50 population matched controls.  Immunohistochemical staining was performed on 
a subset of 20 patients to assess the presence of the p53 protein within cells.  These results 
were correlated to the mutation analysis of the TP53 gene for the above mentioned subset 
patients.   
RESULTS: Variants identified within the promoter region of the HAMP gene comprise:  
-153 C/T, -188 C/T, -429 G/T and -582 A/G; with the -429 G/T variant being of particular 
interest.  The -429 G/T variant is found to disrupt a previously identified p53 response 
element required for the up-regulation of HAMP gene expression.  The -429 G/T variant was 
found to occur at a low frequency within the general Mixed Ancestry, Caucasian and Black 
South African populations contradictory to the high frequency identified in the Black South 
African patient cohort.  Immunohistochemical results did not correlate high levels of p53 
protein to the occurrence of the -429 G/T variant. 
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CONCLUSIONS:  Variants found within regions crucial to the transcriptional regulation of 
the gene are able to alter gene expression, possibly to a level of disease phenotype exhibition.  
Dysregulation of the HAMP gene results in an increased uptake of dietary iron, which in turn 
could feed the proliferation of carcinogenic cells lines.  The presence of the -429 G/T and -
582 A/G variants indicate a trend in the alteration of HAMP gene expression.  Whether this 
alteration is causative or merely accessory to the cancer phenotype exhibition is a hypothesis 
that warrants further investigation.  Failure of the Immunohistochemical staining procedures 
to correlate the -429 G/T variant presence to altered p53 protein levels does not completely 
exclude the existence of a link concerning the two.  A longer time period may be required for 
p53 protein build-up to occur. 
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Addendum C 
6.2. Patents 
 
Title: Biomarker for Diagnosing Cancer 
Arthors: N. W. McGregor, M. G. Zaahl, T. Matsha 
Field of Invention: This invention relates to the fields of cancer biology and nucleic acid 
biochemistry. Specifically, this invention provides a diagnostic kit for 
use in detecting a susceptibility to Oesophageal Cancer in a subject, 
use of a biomarker for Oesophageal Cancer, a method of detecting a 
susceptibility to Oesophageal Cancer in a subject, and nucleic acid 
segments and compositions for use therefor. 
Patent Number: ZA2008/09634 
Legal: VON SEIDELS, Intellectual Property Attorneys 
 
